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The proper functional interaction between different tissues represents a key component in
systemic metabolic control. Indeed, disruption of endocrine inter-tissue communication is a
hallmark of severe metabolic dysfunction in obesity and diabetes. Here, we show that the
FNDC4-GPR116, liver-white adipose tissue endocrine axis controls glucose homeostasis. We
found that the liver primarily controlled the circulating levels of soluble FNDC4 (sFNDC4)
and lowering of the hepatokine FNDC4 led to prediabetes in mice. Further, we identified the
orphan adhesion GPCR GPR116 as a receptor of sFNDC4 in the white adipose tissue. Upon
direct and high affinity binding of sFNDC4 to GPR116, sFNDC4 promoted insulin signaling and
insulin-mediated glucose uptake in white adipocytes. Indeed, supplementation with
FcsFNDC4 in prediabetic mice improved glucose tolerance and inflammatory markers in a
white-adipocyte selective and GPR116-dependent manner. Of note, the sFNDC4-GPR116,
liver-adipose tissue axis was dampened in (pre) diabetic human patients. Thus our findings
will now allow for harnessing this endocrine circuit for alternative therapeutic strategies in
obesity-related pre-diabetes.
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Type 2 diabetes (T2D) is a gradually developing disease inwhich genetic, lifestyle, and ageing factors each mayseparately, or in combination, accelerate its progression
and severity. Early glucose intolerance is a hallmark of the pre-
diabetic state and it is targeted therapeutically by the prescription
of metformin or lifestyle changes, such as diet and exercise1,2.
However, there is a lack of mechanistic understanding of pre-
diabetes development, as well as the endocrine and molecular
factors, that can explain the individual responsiveness to ther-
apeutic interventions.
Of the plethora of biological responses elicited by insulin,
the removal of excess glucose from the blood circulation is central
in the pathogenesis of obesity-related T2D. Progressive insulin
resistance and the subsequent failure to cope with dietary glucose,
i.e., glucose intolerance, mostly reflects the inability of the adipose
tissue (AT) and skeletal muscle to sufficiently eliminate circulating
glucose in response to insulin. In this pre-diabetic state, improve-
ments in insulin sensitivity are in principal still able to delay or even
prevent the onset of full-blown diabetes, making this disease stage
an attractive target for tailored interventions and preventive mea-
sures. However, mechanisms contributing to the glucose-intolerant,
pre-diabetic phenotype remain vastly unclear.
Recent research progress has clearly promoted the concept that
systemic glucose homeostasis is determined by a variety of inter-
tissue communication pathways, and most peripheral organs have
been described to exhibit a secretory, endocrine function, including
the liver. Indeed, hepatic steatosis is the strongest predictor of
insulin resistance in skeletal muscle and AT, tightly coupled to
alterations in the hepatic secretory function and the release of so-
called hepatokines that are capable of controlling distant metabolic
processes3. Understanding of specific endocrine routes by which the
liver regulates insulin action in distinct peripheral organs has just
emerged, with critical mechanisms remaining to be discovered.
Fibronectin type III domain containing 4 (FNDC4) is a type I
transmembrane protein, which has been demonstrated to release
a soluble bioactive protein that is highly conserved among mouse
and primates4. Soluble FNDC4 (sFNDC4) has been reported to
exert anti-inflammatory effects on macrophages4, osteoclasts5,
and adipocytes6, promoting survival in response to severe chronic
inflammation4 and improving insulin resistance6. Our under-
standing of FNDC4 biology has only just begun and it is unclear
to date whether this secreted protein acts as a hormone. In this
regard, the receptor and its signaling, as well as target organs of
sFNDC4 remain unknown; it is unclear whether and how
sFNDC4 acts in an endocrine manner to maintain glucose
homeostasis. Here, we report an as-yet undiscovered physiologi-
cal role of FNDC4 as a hepatokine. We show that the liver pri-
marily controlled the circulating levels of sFNDC4 and that
lowering of hepatic FNDC4 resulted in a pre-diabetic phenotype
in mice. Indeed, we demonstrate that circulating levels of
sFNDC4 in several human and mouse cohorts showed tight
correlation with insulin sensitivity. In addition, we now have
identified the orphan adhesion G protein-coupled receptor 116
(GPR116) as a receptor of sFNDC4 in white adipose tissue
(WAT), thereby establishing an endocrine FNDC4–GPR116 axis
in the control of systemic glucose homeostasis. Intriguingly, this
axis was impaired in diabetic patients and therapeutic injections
of recombinant FcsFNDC4 into pre-diabetic mice corrected pre-
diabetic hyperglycemia, now providing a rationale for harnessing
the FNDC4–GPR116 axis in pre-diabetes therapy.
Results
Liver and serum FNDC4 levels positively associate with glucose
tolerance in humans. Using tissue mRNA profiling, we found
Fndc4 mRNA to be most highly expressed in the liver and brain
of mice and humans (Fig. 1a). To investigate the association of
FNDC4 with glycemic control in humans, we measured the
mRNA levels of liver and AT FNDC4 from lean and obese
humans with or without T2D (see “Methods: Cross-sectional
study—Leipzig”). Liver FNDC4 mRNA levels showed an inverse
correlation with fasting blood glucose levels (Fig. 1b and Sup-
plementary Table 1) and blood glucose levels after a 2-h oral
glucose tolerance test (OGTT) (Fig. 1c and Supplementary
Table 1) in lean healthy individuals. Since lower levels of blood
glucose in those tests indicate increased glucose tolerance, these
findings proposed a positive correlation between FNDC4 levels
and glucose tolerance, as well as insulin sensitivity. In addition,
liver FNDC4 mRNA levels decreased in obese humans with
impaired glucose tolerance and impaired insulin tolerance (IGT/
IIT) and in obese subjects with clinically diagnosed T2D com-
pared to normoglycemic, non-diabetic (ND) lean controls
(Fig. 1d and Supplementary Table 1).
FNDC4 has been shown to release a soluble peptide (sFNDC4)4
and there are limited reports of sFNDC4 levels in the blood
circulation of humans or mice. Therefore, we quantified sFNDC4 in
human serum in a cohort of healthy individuals receiving a high-fat
diet (HFD), isocaloric to the control diet, for 6 weeks. Blood was
collected for analysis after 1 and 6 weeks (see “Methods: NUGAT
study”). Under this diet, the participants did not gain weight, but
showed an increased Homeostasis Model Assessment (HOMA)
index, indicating the appearance of insulin resistance in response to
the consumed HFD7. We observed a 10% decrease and a sustained
decrease of 6% compared to baseline (LF), in the serum sFNDC4
levels, following 1 week and 6 weeks HFD, respectively (Fig. 1e).
Thus, under these early pre-diabetes settings, circulating levels of
sFNDC4 showed a significant decrease in humans. Overall, these
data supported a positive correlation between liver FNDC4 mRNA,
serum sFNDC4 levels, and glucose tolerance as well as insulin
sensitivity in humans (See also Supplementary Note 1: FNDC4
ELISA-FNDC4 quantification in plasma or serum- ELISA Valida-
tion and related Supplementary Fig. 1.).
Hepatic FNDC4 is required for proper systemic glucose tol-
erance and specifically targets WAT. To determine the role of
hepatic FNDC4 in glucose homeostasis, we lowered hepatic
FNDC4 levels using an AAV8-shFNDC4 specifically targeting the
liver. To confirm the knockdown (KD) effect of the adeno-
associated virus (AAV), we measured liver and circulating
FNDC4 3 weeks post AAV injection and then split the AAVsh-
Control and AAVshFNDC4-injected animals into HFD or chow
diet groups for a total of 8 weeks (Fig. 2a). Three weeks after the
delivery of AAVshFNDC4, liver Fndc4 mRNA decreased by 40%
(Fig. 2b), and both liver FNDC4 protein (Fig. 2c) and sFNDC4
plasma levels (Fig. 2d) were significantly reduced. In addition,
Fndc4 mRNA was not altered in non-hepatic tissues, such as
gonadal WAT (gWAT) and skeletal muscle (gastrocnemius
muscle) (Fig. 2b), supporting the notion that the liver represents
the main source of circulating FNDC4. Finally, at the end of the
study (8 weeks on HFD and total 11 weeks post AAV injections),
liver Fndc4 mRNA (Fig. 2e) as well as circulating levels of
sFNDC4 (Fig. 2f) still remained significantly reduced in the
AAVshFNDC4 group compared to the AAVshControl group
under chow and HFD conditions. Of note, we observed sub-
stantial differences with regard to the quantified levels of sFNDC4
in mouse plasma derived from trunk blood as opposed to tail
blood, with tail plasma measurements of sFNDC4 being up to 10
times lower compared to trunk-derived plasma (see Supplemen-
tary Note 1 and Supplementary Figs. 1g and 2a, b).
Under chow diet, AAVshFNDC4 treated mice showed no
difference in glucose clearance during an intraperitoneal glucose
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Fig. 1 Liver and serum FNDC4 levels positively associate with glucose tolerance in humans. a RT-qPCR quantification of mRNA levels of the mouse (left
panel, n= 3 mice per tissue, male, C57Bl6N, 7–8 weeks old, skeletal muscle is quadriceps) and the human Fndc4 gene in the indicated tissues (right panel,
n are shown on the figure and represent independent humans). Left panel: 2∧ddCt values are shown, which are expressed relative to Fndc4mRNA levels for
the Sk.muscle group. Tbp is used as a housekeeping gene. Right panel: The human data were retrieved from the Protein Atlas Project database (URL:
http://www.proteinatlas.org/search/Fndc4) and represent pTMP (read counts normalized to transcripts per million coding genes). Exact values are
provided in the Source Data. Pearson’s correlation for human liver FNDC4 mRNA levels and fasting blood glucose levels (mmol/l) (b) and c blood glucose
levels (mmol/l) 2 h post oral glucose tolerance test (OGTT) (n= 12 independent humans). d RT-qPCR quantification of human liver FNDC4mRNA levels at
the indicated groups. ND non-diabetic, T2D type 2 diabetes, Obese-IGT/IIT impaired glucose tolerance/impaired insulin tolerance (“Methods: Cross-
sectional study—Leipzig”) (n represents independent humans and exact numbers per group are shown on the figure). Statistics represent unpaired two-
tailed t test. mRNA levels are provided as mRNA quantity (calculated based on the standard curve method). e Serum levels of sFNDC4 ng/ml in paired
blood samples from humans, who initially consumed a low-fat (LF) diet for 6 weeks and subsequently were given a high fat (HF) diet for 6 weeks
(“Methods: NUGAT study-DIfE”). Serum was collected at the end of the LF diet period (LF) and at 1 week (HF 1 week) and 6 weeks (HF 6 weeks) of HFD
diet (paired samples), n= 92 independent humans. Statistics represent paired, two-tailed t test. Data shown are mean ± SEM.p p-value, ns non-significant.
Source data are provided as a Source data file.
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tolerance test (IPGTT) (Fig. 2g); however, they exhibited
compensatory hyperinsulinemia during the IPGTT (Fig. 2h)
and showed no significant difference during an insulin
tolerance test (ITT) compared to the AAVshControl mice
(Fig. 2i). Furthermore, AAVshFNDC4 mice on HFD tended to
have higher blood glucose at 4 weeks of HFD and showed
impaired glucose clearance at 8 weeks of HFD compared to the
AAVshControl animals, during the IPGTT (Fig. 2j, k).
Importantly, at 4 weeks on HFD AAVshFNDC4 showed severe
compensatory hyperinsulinemia during the IPGTT (Fig. 2l).
There was no significant difference between the two groups in
the ITT at 8 weeks on HFD (Fig. 2m).
To examine the possible effects of AAVshFNDC4 liver deletion
on insulin secretion, we also examined the levels of fasting and
glucose-stimulated C-peptide and found no difference between
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conditions (Supplementary Fig. 2c, d). Furthermore, the insulin
content in the pancreas of AAVshFNDC4 mice was not
significantly different from that of the AAVshControl group on
chow or HFD (Supplementary Fig. 1e), nor did recombinant
FNDC4 alter insulin secretion in primary pancreatic islets in vitro
(Supplementary Fig. 2f). Our findings suggested an intact
pancreatic function in the AAVshFNDC4 treated group and
argued for an increased peripheral insulin resistance resulting in
hyperinsulinemia compared to the AAVshControl treated group.
Finally, no differences in body weight (Supplementary Fig. 2g, j),
organ weights (Supplementary Fig. 2i, l), and food intake
(Supplementary Fig. 2h, k) between AAVshFNDC4 compared
to AAVshControl were observed neither under chow nor under
HFD conditions. Furthermore, there were no significant differ-
ences in liver or muscle triglyceride (TG) content between
AAVshFNDC4 and AAVshControl under chow or HFD diet
(Supplementary Fig. 2m, n). Serum cholesterol (Supplementary
Fig. 2o), TG (Supplementary Fig. 2p), and non-esterified fatty
acid (NEFA) levels (Supplementary Fig. 2q) also remained
unchanged between AAVshFNDC4 and AAVshControl groups,
under HFD conditions. Overall, these findings demonstrate that
decreasing liver and circulating FNDC4 promoted a state of pre-
diabetes, manifested by glucose intolerance combined with
compensatory hyperinsulinemia and subsequent hyperglycemia.
To identify the tissue target(s) of sFNDC4, we injected
recombinant mammalian, long-lived FcsFNDC4 to HFD mice
with glucose intolerance and traced tissue glucose uptake after
long-term injections. To determine the injected dose of
recombinant sFNDC4, we examined the circulating levels of
sFNDC4 in mice under chow and HFD feeding. sFNDC4 was
present in the circulation throughout the day but tended to peak
several hours before the mice entered the feeding/dark phase
(Fig. 3a). Remarkably, HFD feeding reduced the circulating levels
of sFNDC4 (Fig. 3a) and decreased liver mRNA levels of Fndc4
(Fig. 3b). We found that intraperitoneal (ip) injections of long-
lived FcsFNDC4, at a dose of 0.2 mg/kg every second day,
recovered the decreased levels of sFNDC4 in the HFD group
to the normal levels of the chow fed group (Fig. 3c). Therefore, we
used the dose of 0.2 mg/kg, injected every second day to treat
HFD-fed mice. Under these conditions, we observed an
improvement in glucose tolerance after 2 weeks (Fig. 3d, e),
which was maintained for up to 4 weeks upon injections (Fig. 3d,
e). We saw no differences in glucose-stimulated insulin secretion
(Fig. 3f) and insulin tolerance (ITT) (Fig. 3g) between FcsFNDC4
and vehicle control (VC)-treated mice. Also, body weight
(Supplementary Fig. 3a) and food intake (Supplementary Fig. 3b)
were not altered. Furthermore, we found no difference in organ
weights (Supplementary Fig. 3c) or in liver and muscle TGs
(Supplementary Fig. 3d–f), which suggested that changes in lipid
content in those metabolic tissues could not have accounted for
the improved glucose clearance during the IPGTT upon chronic
FcsFNDC4 injections.
To examine the tissues contributing to the improved glucose
clearance during the IPGTT, we evaluated the glucose uptake in
different tissues using fluorescently labeled glucose (2-NBDG (2-
(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose)).
We found a significantly higher uptake of fluorescent glucose in
the gWAT of HFD mice injected with FcsFNDC4 compared to
VC (Fig. 3h). In addition, we only observed an increase in WAT
pAKT levels of FcsFNDC4-treated HFD mice (4 weeks) com-
pared to VC after a single ip injection of insulin, whereas this
effect was absent in liver and skeletal muscle (Fig. 3i), supporting
an insulin-sensitizing effect of FcsFNDC4 specifically in WAT.
Closer histological examination of the gWAT showed no
difference in adipocyte size (Fig. 3j) but reduced Cd68-positive
cells upon FcsFNDC4 injections (Fig. 3k, l), suggesting a reduction
of macrophages in gWAT of FcsFNDC4-injected mice compared
to VC controls. In addition, FscFNDC4 mice had lower total tissue
Cd68 mRNA in the gWAT compared to VC controls (Fig. 3m).
mRNA levels of Resistin, Tnfalpha (tumor necrosis factor-α), Mcp-
1 (monocyte chemoattractant protein-1), Ccl11 (CC motif
chemokine 11), Il10 (interleukin 10), Il6 (interleukin-6), and
Cd206 (cluster of differentiation 206) were decreased in gWAT of
FcsFNDC4 versus VC treated mice (Fig. 3n), indicating a reduced
inflammatory status in this tissue upon FcFNDC4 delivery.
Furthermore, FcsFNDC4-treated mice exhibited reduced levels of
circulating TNFalpha (Fig. 3o) and Resistin proteins (Fig. 3p), the
latter being specifically secreted fromWAT in mice8. We found no
difference in circulating leptin (Supplementary Fig. 3g) and
adiponectin (Supplementary Fig. 3h) between FcsFNDC4-
injected mice compared to VC group. To investigate whether
those effects were associated with improvement of endoplasmic
reticulum (ER) stress as it has been suggested for sFNDC4 before6,
we quantified ER stress markers, such as Edem (ER-degradation-
enhancing-α-mannidose-like protein), Xbp1 (X-box binding pro-
tein 1), Grp78 (Glucose regulated protein 78), Atf6 (activating
transcription factor 6), Grp94 (Glucose regulated protein
94), DNAjb9 (DnaJ Heat Shock Protein Family Member 9), Erdj4
Fig. 2 Mice with hepatic deletion of FNDC4 exhibited decreased circulating levels of sFNDC4 and developed a pre-diabetes phenotype. a Schematic
representation of the study protocol. b RT-qPCR quantification of Fndc4 mRNA at the indicated tissues (n= 5 mice per group for the liver and skeletal
muscle (gastrocnemius) and n= 7 mice per group for gonadal white adipose tissue (gWAT). cWestern blot against FNDC4 protein in the liver and VCP as
loading control (n= 2 mice per group are shown). Results on additional mice and uncropped blots are shown in Source data. d ELISA quantification of
plasma (trunk blood) sFNDC4 (n= 5 mice per group), 3 weeks post intravenous (iv) injection of AAVs. e RT-qPCR quantification of Fndc4 mRNA at the
indicated tissues (n= 5 mice for Liver ChowAAVshControl, Liver HFDAAVShFNDC4, n= 4 mice for Liver ChowAAVshFNDC4, and n= 6 mice for Liver
HFDAAVshControl, gWAT ChowAAVshControl, gWATChowAAVshFNDC4, gWAT HFDAAVshControl, gWAT HFDAAVshFNDC4, Sk.muscle
ChowAAVshControl, Sk.muscle ChowAAVshFNDC4, Sk.muscle HFDAAVshControl, Sk.muscle HFDAAVshFNDC4). Skeletal muscle is gastrocnemius. For
b, e, 2^ddCt values are shown, which are expressed relative to the Sk.muscle group. Hprt is used as a housekeeping gene for liver and gWAT and H3f3 is
used as a housekeeping gene for Sk.muscle. f ELISA quantification of plasma (trunk blood) sFNDC4 (n= 8 mice ChowAAVshControl, n= 6 mice
ChowAAVshFNDC4, n= 7 mice HFDAAVshControl, n= 8 mice HFDAAVshFNDC4) 11 weeks post iv injection of AAVs and 8 weeks on HFD or chow
control diet. Statistics represent unpaired two-tailed t test. Data point in square was not taken into account for the statistics, due to very high levels of
sFNDC4 compared to the rest of the mice in the group (outlier). Glucose homeostasis in chow and HFD fed mice: g blood glucose and h plasma insulin
levels during an IPGTT. i blood glucose levels during an ITT on chow-fed mice. j Blood glucose levels, k area under the curve (refers to j), and l plasma
insulin during an IPGTT on HFD-fed mice (weeks on HFD as shown on graph). m Blood glucose levels during an ITT on HFD-fed mice. In g, h, j, m, n=
independent mice and the exact number of mice is shown on the figure. Male, C57BL6N mice were put on HFD when 10–11 weeks old and compared with
age-matched chow fed mice. HFD contained 45% fat. During IPGTT and glucose-induced insulin test, 2 g/kg D-glucose was injected (ip) and during ITT
0.8 U/kg insulin was used (ip). p p-value, ns non-significant. Data shown are mean ± SEM. Statistics in b, d–f, h, j–m represent an unpaired, two-tailed
Student’s t test. Source data are provided as a Source data file.
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(ER-localized DnaJ type II homolog 4), Chop (CCATT-enhancer-
binding protein homologous protein), as well as a regulator of ER
stress, Hmox1 or HO-1 (heme oxygenase 1), in the WAT tissue of
FcsFNDC4- and VC-treated HFD mice, but we observed
no difference in the expression levels of ER stress gene markers
between those groups (Supplementary Fig. 3i). In addition, to
assess FcsFNDC4 on ER stress directly on adipocytes, we incubated
3T3L1 adipocytes with palmitate (PA) (200 μM) and FcsFNDC4
(200 nM) or Fc control (200 nM) for 24 h and blotted against
activated master ER stress regulator inositol-requiring enzyme 1
(IRE1). We found no impact of FcsFNDC4 on the protein levels of
PA-induced pIRE1 on 3T3L1 adipocytes treated 24 h with PA, as
opposed to Fc control plus PA treated group (Supplementary
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WAT insulin signaling by FcsFNDC4 derived from alleviation of
ER stress as previously published by Lee et al.6.
Finally, to exclude any effects of FcFNDC4 on energy
expenditure (EE), also linked to alterations in systemic inflam-
mation, we measured EE in either HFD-fed mice treated
chronically with FcFNDC4 (Supplementary Fig. 3k–q) or in lean
young, chow diet fed mice 2 h after a single injection of
FcsFNDC4 (Supplementary Fig. 3r, s). In both cases, no
differences in EE per se or in correlation to body weight between
FcsFNDC4-injected and control mice was observed (Supplemen-
tary Fig. 3k–m and Supplementary Fig. 3r), as there were also no
differences in locomotor activity (Supplementary Fig. 3q, s),
respiratory exchange ratio (RER; Supplementary Fig. 3p), and
oxygen consumption (Supplementary Fig. 3o). Also, we observed
no differences in cumulative food consumption (data not shown).
Thus, our findings supported a specific action of FcsFNDC4 in
the WAT, independent of EE but linked to improved glucose
uptake, improved insulin signaling, and reduced levels of pro-
inflammatory adipokines, as well as a local reduction of
macrophages in the gWAT.
GPR116 acts as a receptor for sFNDC4. To initially identify
candidate receptors for sFNDC4, we set up a fluorescence-
readout binding assay in live cells. To this end, we utilized
recombinant sFNDC4, corresponding to the extracellular part of
FNDC4 protein (mouse FNDC4 aa: 40–160) fused with human
IgG (Fc). The binding of FcsFNDC4 to cells was quantified
by detecting the cell-bound ligand (FcsFNDC4) with secondary
IgG-PE (phycoerythrin) conjugated antibody using fluorescent
flow cytometry. For screening, we chose immortalized mouse pre-
adipocytes (imm. SVF) from inguinal WAT9 due to their higher
survival and robustness during the fluorescence-activated cell
sorting (FACS) staining/sorting protocol, the possibility to sort
higher numbers, and to ensure reproducibility. We performed
saturation binding with increasing concentrations of FcsFNDC4
from 0 to 500 nM (see also Supplementary Note 2). We assessed
the total population of cells (Supplementary Fig. 4a) and we
observed increasing levels of fluorescence intensity (phycoery-
thrin (PE)) following the increasing FcsFNDC4 concentration
(Supplementary Fig. 4b). By performing a saturation binding
curve, we observed saturation of fluorescence readouts around
100 nM of FcsFNDC4. In contrast to FcsFNDC4, the binding of
Fc control did not show any saturation of fluorescence (Fig. 4a).
We thus used Fc as a negative control in our assays. Furthermore,
by utilizing a competitive sFNDC4-binding assay we observed
a sFNDC4 concentration-dependent reduction on the binding of
FcsFNDC4, supporting the idea of specific binding to a mem-
brane receptor (Fig. 4b).
Next, high- and low-binding cell populations (HBC and LBC,
respectively; Fig. 4c) were sorted, expanded, and re-sorted for up
to 20 passages to obtain cell populations with stable high and low
binding properties to FcsFNDC4 (Fig. 4d). These final HBC and
LBC were analyzed for differentially expressed genes by
Affymetrix transcriptomics analysis. Among the top 30 upregu-
lated genes, we identified two G protein-coupled receptors
(GPCRs) and an integrin receptor to be more highly expressed
in HBC compared to LBC: relaxin/insulin-like family peptide
receptor 1 (Rxfp1, fold change= 16), G protein-coupled receptor
116 (Gpr116, fold change= 10), and integrin subunit alpha D
(ItgaD, fold change= 9) (Fig. 4e). RXFP1 ligands are relaxins and
insulin-like peptide 3 (INSL3)10. GPR116 is an orphan adhesion
GPCR and integrin receptors are known to interact with FN3
domain-containing proteins11,12. To test the impact of these
candidate receptors on FcsFNDC4 binding, we transiently
overexpressed human RXFP1, GPR116 or ITGAD in HEK239A
cells (Fig. 4g), a cell line that showed much lower baseline binding
to FcsFNDC4 than the immortalized pre-adipocytes (Supple-
mentary Fig. 4c, d). GPR116 overexpression (OE) increased the
binding of FcsFNDC4 compared to control, whereas RXFP1 or
ITGAD OE did not have any impact on FcsFNDC4 binding
(Fig. 4f). Ligand binding to integrin receptors requires divalent
cations such as Ca2+ and Mg2+13. Thus, to further test whether
an integrin receptor could possibly mediate the binding of
FcFNDC4, we performed FcsFNDC4 binding in the presence of
increasing concentrations of EDTA chelator, thereby inhibiting
ligand binding to integrins. We did not observe any effect of
EDTA on FcsFNDC4 binding. Only very high concentrations of
EDTA (10 mM) abolished binding (Fig. 4h), overall supporting
the hypothesis that GPR116 represents a specific sFNDC4 target
receptor. Also, we confirmed the higher expression of GPR116 in
HBC versus LBC at the mRNA and protein levels (Supplementary
Fig. 4e).
To further assess the specificity of FcsFNDC4 binding to
GPR116, we performed dose binding of FcsFNDC4 and Fc control
to wild-type (WT), GRP116+/− (HET), and GPR116−/− (knock-
out (KO)) SVF-derived mouse primary preadipocytes from the
inguinal WAT fat depot. We found that FcsFNDC4 binding
decreased upon reduced levels of Gpr116mRNA (Fig. 4i) suggesting
that expression levels of Gpr116 determined the binding of
FcsFNDC4. To further assess direct and specific binding of
Fig. 3 Every second day, injections of rec. FcsFNDC4 0.2mg/kg improved glucose tolerance and increased glucose uptake specifically in the white
adipose tissue. a Plasma (trunk) sFNDC4 in mice on 16 weeks HFD (n= 4 independent mice per time point) and Chow control mice (n= 2–4 independent
mice per time point). Statistics represent a regular two-way ANOVA for diet (Pdiet) and time (Pzt). Multiple comparisons for diet effect were performed
according to Holm–Sidak’s test and exact p values are shown for chow–HFD diet comparison for each time point. b RT-qPCR quantification of liver Fndc4
mRNA at 16 weeks HFD and Chow mice (n= 4 mice per group). c Plasma (trunk) sFNDC4 ng/ml from chow and 14 weeks HFD, 48 h after a single ip
injection of FcsFNDC4 (0.2 mg/kg) or VC (n= 6 mice per group for Chow VS and HFD VC, n =7 mice per goup for HFD FcsFNDC4). d Blood glucose
during IPGTT test, e area under the curve (AUC), f glucose-stimulated insulin response (during the IPGTT) in d, e (d–f n= 7 mice per group), and g
percentage of blood glucose levels during an ITT using 0.8 U/kg insulin ip, (VC—n= 6 mice, FcsFNDC4—n= 7 mice) on HFD, 2 and 4 weeks injected with
VC or FcsFNDC4. h Quantification of 2-NBDG glucose content at shown tissues, 35 min after ip 2-NBDG injection (n= 4–6 mice per group, exact numbers
per group are provided in Source data). iWestern blot of pAKT(Ser473) and total AKT at the indicated tissues, after an acute injection of insulin. pAKT and
AKT were run on different blots, with VCP and beta actin as loading controls, respectively. This experiment was performed once under the exact same
conditions. jMean cell size of adipocytes and k percentage of Cd68-positive area of gWAT (j, k VC—n= 6 mice, FcsFNDC4—n= 8 mice). l Representative
images (out of 20 images per mouse, VC—n= 6 mice, FcsFNDC4—n= 8 mice) for hematoxylin and eosin (H&E) and anti-Cd68 staining of gWAT. Scale
bar= 200 µm. m, n RT-qPCR quantification of mRNA levels of the presented genes in gWAT (VC—n= 6 mice and FcsFNDC4—n= 8 mice). Data shown
represent 2^ddCt values. H3f3 was used as a housekeeping gene. ELISA quantification of o plasma TNFalpha (VC—n= 6 mice and FcsFNDC4-—n= 7
mice) and p serum resistin (VC—n= 6 mice and FcsFNDC4—n= 9 mice). For h–p HFD mice, 4 weeks injected with VC or FcsFNDC4 are shown. HFD
contained 60% fat and it was initiated at 7–8 weeks of age. Mice were males, C57BL6N. Data shown are mean ± SEM. Statistics are unpaired, two-sided t
test. p p-value, ns non-significant. Source data are provided as a Source data file.
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sFNDC4 to GPR116, we performed a GPR116 pull-down assay
using FcsFNDC4 as bait. FcsFNDC4 precipitated GPR116 from
total cell lysates of NIH3T3 cells, whereas there was no GPR116
precipitation with the Fc control (Fig. 4j). We have validated the
specificity of the antiGPR116 (ab136262) used to detect GPR116 in
Fig. 4j, in NIH3T3 preadipocytes with lenti-ShGPR116 KD and
lenti-shControl. At cells with 70% deletion of GPR116 (shGPR116)
compared to control cells (shControl) (Supplementary Fig. 4f), this
antibody showed no band close to 250 kDa and a much weaker
band a bit higher than 130 kDa (all bands corresponding to the N-
terminus of GPR116; Supplementary Fig. 4g).
FNDC4 and GPR116 crystal structures do not exist yet. Based
on the interaction model of the GPR56 extracellular (EC) GAIN
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indicated certain predicted similarities for the interaction of
FNDC4-GPR116, we hypothesized that FNDC4 might interact
with the EC fragement of GPR116 (Supplementary Fig. 4h).
Therefore, we employed a GPR116 N-terminal EC targeting
antibody to investigate whether such antibody would abolish
FcsFNDC4 binding in live cells. We checked the specificity of this
antibody (ab111169) in 3T3L1 mature adipocytes treated with
lenti-shGPR116 to induce deletion of endogenous GPR116 and
lenti-shControl lentivirus treated adipocytes (Supplementary
Fig. 4i, j). Indeed, in HEK293T GPR116 OE cells incubated with
anti-GPR116 prior to FcsFNDC4 or Fc binding (100 nM) we
observed an anti-GPR116 dose-dependent decrease in the binding
of FcsFNDC4 compared to isotype control or Fc control (Fig. 4k),
thus supporting that FcsFNDC4 binds to the extracellular part of
GPR116.
To estimate the binding affinity of FcsFNDC4 to GPR116, we
stably overexpressed human GPR116 (with C-terminal fused
FLAG) in HEK293A and HEK293T cells. We confirmed equal
levels of GPR116 overexpression (OE) in both cell lines by
blotting against FLAG (Supplementary Fig. 4k). Of note, we
measured endogenous GPR116 mRNA levels in HEK293T cells
and found no detectable expression of GPR116 in those cells, as
opposed to HEK293A cells (HEK293T Ct > 32) (Fig. 4l). Using
the above-described fluorescent flow cytometry binding assay, we
created saturation binding curves of FcsFNDC4 and Fc control to
HEK cells GPR116 OE or mock controls (Fig. 4m, n). In both
HEK cell lines, only binding of FcsFNDC4 to GPR116 OE cells
showed binding saturation (Fig. 4m, n). In contrast, binding of
FcsFNDC4 to mock-transfected control was very low and did not
saturate in HEK293A cells (Fig. 4m). In HEK293T mock-
transfected cells, which express no endogenous GPR116,
FcsFNDC4 binding was completely absent, similar to Fc control
binding (Fig. 4n). Competition binding with excess native
sFNDC4 abolished FcsFNDC4 binding, supporting specific
binding of FcsFNDC4 in HEK293T GPR116 OE cells. These
experiments estimated specific binding of FcsFNDC4 to GPR116
with an equilibrium dissociation constant, Kd= 33 ± 10 nM in
HEK293A cells (Fig. 4m) and Kd= 25 ± 5 nM in HEK293T cells
(Fig. 4n).
GPR116 is required for the insulin-sensitizing effects of
FcsFNDC4 in adipocytes. Our data thus far suggested that the
FNDC4–GPR116 axis specifically acts via liver–WAT communica-
tion. To delineate the role of AT GPR116 in the FcsFNDC4 effects
on glucose homeostasis, we generated AT-specific GPR116 KO mice
(GPR116Ad−/−), using adiponectin Cre-mediated gene targeting
in GPR116 flox site-carrying mice. HFD-fed GPR116Ad−/−
and GPR116Adf/f mice were treated with FcsFNDC4 or Fc control
for 4 weeks by ip delivery of 0.2 mg/kg every second day. Of note,
FcsFNDC4 improved glucose tolerance only in GPR116Adf/f mice
but not in the GPR116Ad−/− littermates, whereas Fc control
injections did not have any effect in neither genotype (Fig. 5a, b).
Fig. 4 Identification of GPR116 as a candidate receptor for sFNDC4. a Saturation binding curves of FcsFNDC4 and Fc control to immortalized SVF (imm.
SVF) preadipocytes derived from mouse iWAT. Y-axis shows ligand binding as mean fluorescence intensity (MFI) per 10,000 cells. Three replicate wells
are shown per concentration of rec. protein. This experiment was repeated at least three times. b Competition of FcsFNDC4 binding (500 nM) with
increasing concentrations of untagged sFNDC4. Data are expressed as percentage of max binding of 500 nM FcsFNDC4 (n= 3 independent experiments).
Bars represent mean of three independent experiments ±SEM. c Gating of sorted cell populations of imm. SVF iWAT to very high log.PE/log.FITC signal
(top 2.25% from total cell population=HBC-high binding cells) versus very low log.PE/log.FITC signal (bottom 3.92% from total cell population= LBC-low
binding cells), positive for FcsFNDC4 binding (100 nM). This sorting was performed 20 times. d Binding of FcsFNDC4 (20 nM) and Fc control (20 nM) or
only IgG-PE (PE) secondary in cells sorted from c after resorting and reseeding for 20 passages. Bars correspond to binding shown as MIF per 10,000 cells.
This experiment was performed several times (20 times) up to passage 20 (n= 4 replicate wells). e Fold change mRNA expression data presented as a
heat map. Top 35 genes identified with fold change HBC versus LBC >1.5 and p < 0.05 from Affymetrix gene expression arrays comparing LBC and HBC.
Receptor genes are underlined. Color scale of fold change values is shown below the heat map. The means of three replicate wells per group (LBC and
HBC) are compared. Absolute values and fold change calculations are presented in the Source data. The Affymetrix microarray data have been submitted
to GEO (gene expression omnibus) under the identification GSE165329. Affymetrix arrays were performed once. f Fold change of binding (MFI) per 10,000
cells of FcsFNDC4 (100 nM) to HEK293A cells with transient overexpression of human RXFP1 or human GPR116 or human ITGAD. Binding to a mock
transfection control (lipofectamine only) was used as control. n= 3 replicate wells of a representative experiment out of two independent experiments is
shown. g (left and right panel) RT-qPCR quantification of the indicated genes at the indicated conditions. n= 4 replicate wells per condition are shown. This
analysis was performed only once. TBP is used as a housekeeping gene. 2^ddCt values are shown. h Competition of FcsFNDC4 (100 nM) binding with
increasing concentrations of EDTA (0–103 µM). Values are binding shown as MFI per 10,000 cells. n= 3 replicate wells of a representative experiment out
of two independent experiments is shown. Cells are primary mouse SVF preadipocytes (iWAT). i Binding (MFI) of the indicated concentrations of
FcsFNDC4 or Fc control to mouse SVF preadipocytes (iWAT) from WT, GPR116+/−, and GPR116−/− mice. n= 1 replicate well of cells pooled from n=
7–8 mice per genotype per tested concentration of rec. protein. This experiment was performed once. Mice were male, 7–9 weeks old. (i—top panel) RT-
qPCR quantification of mRNA levels of Gpr116 in SVF iWAT preadipocytes used for binding in i at the indicated genotypes (n= 3 independent mice per
genotype). Tbp is used as a housekeeping gene. j Pull down for GPR116: western blot analysis against GPR116. For pull down, 6xHis Dynabeads were
prebound with 6xHis-Fc and 6xHis-Fc-sFNDC4 (30 µg), followed by incubation of 300 µg NIH3T3 cell lysates. (+) added to beads, (−) not added to
beads, Input: rec. protein or cell lysates added to the Dynabeads. Unretained: cell lysates proteins that did not immunoprecipitate to the beads. Eluted:
elution of GPR116, which precipitated on 6xHis-Fc-fused protein prebound to beads. Similar results were obtained from three independent experiments.
Antibody against GPR116: ab136262. Representative WB out of three independent experiments is shown. Uncropped blot image is shown in Source data.
k Mean fluorescence intensity (MFI) representing binding of FcsFNDC4 (100 nM) or Fc control (100 nM) to HEK293T GPR116 (human) OE cells in the
presence of the indicated dose of antiGPR116 antibody, against the N-terminus of GPR116 (ab111169) or isotype control (ab171870). This experiment was
performed once with n= 3 technical replicates. l q-PCR quantification of human Gpr116 mRNA levels in HEK293A (Ct= 25) and HEK293T (Ct=
undetected) cells, n= 3 replicate wells per group. This quantification was performed once. m, n Saturation binding on HEK293A (m) or HEK293T (n) cells
with stable human GPR116 OE or mock cells after incubation with the indicated concentrations of FcsFNDC4 or Fc control. For n, FcsFNDC4 binding was
also performed in excess of sFNDC4 (1 mM) to determine non-specific binding (NSB). Calculated equilibrium binding constant (Kd) is shown for total
binding in m and specific binding in n. In m, n, n= 3 replicate wells are shown of a representative experiments out of three independent experiments. In b,
d, f–i (top panel), k, data are shown as mean ± SEM. Statistical analysis in b, d, f–i (top panel) represents unpaired two-tailed t test. For a, b, f, h, i, k, m, n, a
representative gating is shown in Supplementary Fig. 1a. All cells were gated and thus MFI values were derived always from all assessed cells. Source data
are provided as a Source data file.
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h
Fig. 5 HFD fed GPR116Ad−/− mice did not improve glucose tolerance in response to FcsFNDC4 therapeutic injections as opposed to GPR116Adf/f mice.
a Blood glucose during IPGTT test at the indicated time points and area under the curve (b). c Glucose-stimulated insulin response during the IPGTT in a, b.
d Blood glucose as percentage of baseline glucose levels during an ITT. e Body weight, f organ weight, g serum resistin, and h plasma TNFalpha at the
indicated groups. White bars: GPR116Adf/f Fc-injected mice, red bars: GPR116Adf/f FcsFNDC4-injected mice, grey bars GPR116Ad−/− Fc-injected mice, red
bars/pattern: GPR116Ad−/− FcsFNDC4-injected. Mice were males, set on a HFD 60% fat when 9–10 weeks old, for 12 weeks. FcsFNDC4 injections were
given at a dose of 0.2 mg/kg every second day for 4 weeks (injections between weeks 8 and 12 of HFD), n= 6–8 mice per group. Exact number of mice are
shown on figures and also described in the Source data. During IPGTT and glucose-induced insulin test, 2 g/kg D-glucose was injected and during the ITT
0.8 U/kg insulin was used ip. In all panels, data are presented as mean ± SEM. Statistics represent unpaired two-tailed t test. p p-value, ns non-significant.
Source data are provided as a Source data file.
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There were no significant differences of FcsFNDC4 on the
glucose-stimulated insulin response (Fig. 5c) and insulin toler-
ance (Fig. 5d) in neither genotype and in comparison to the Fc-
treated controls. Furthermore, we did not observe any difference
of FcsFNDC4 injections on body (Fig. 5e) and organs weights
(Fig. 5f) as compared to the Fc control in both genotypes.
Importantly, GPR116Ad−/− mice on HFD demonstrated signs of
pre-diabetes, manifested by fasting and glucose-stimulated com-
pensatory hyperinsulinemia (Fig. 5c), and tended toward having
higher blood glucose levels during an ITT (Fig. 5d) compared to
GPR116Adf/f. Thus, GPR116Ad−/− mice showed signs of pre-
diabetes similar to the mice with the effects of decreased hepatic
FNDC4 levels (AAVshFNDC4 mice).
To assess whether the observed anti-inflammatory effects of
FcsFNDC4 were also mediated via the AT GPR116, we measured
circulating resistin (Fig. 5g) and TNFalpha (Fig. 5h). FcsFNDC4
injections decreased these inflammatory markers only in
GPR116Adf/f but not in GPR116Ad−/−. Given that GPR116 was
not expressed in macrophages and other immune cells (according
to https://www.proteinatlas.org/ENSG00000069122-ADGRF5
and our own quantifications, Ct values are non-detectable), our
findings supported the conclusion that adipocyte GPR116
mediated both insulin-sensitizing and local inflammation-
lowering effects of FcsFNDC4.
To investigate whether FcsFNDC4 was able to improve insulin
resistance directly in adipocytes and subsequently promote
insulin-stimulated glucose uptake, we utilized a previously
described method of in vitro induced insulin resistance in
3T3L1 mature adipocytes14. Exposure of 3T3L1 mature adipo-
cytes to 10 nM insulin for 16 h (overnight (O/N)) was sufficient to
induce insulin resistance reflected by dampened phosphorylation
of downstream effectors of insulin receptor signaling and
decreased insulin-dependent glucose uptake upon acute insulin
stimulation14. In this paradigm, by using a wide range of
FcsFNDC4 concentrations (1 pM–10 nM) (for ng/ml, see Supple-
mentary Note 2), co-incubation of FcsFNDC4 with insulin for 16
h (O/N) was able to prevent dampening of insulin signaling due
to O/N insulin exposure (Fig. 6a and Supplementary Fig. 5a).
Similar observations were made for AKT substrate pAS160,
which regulates GLUT4 translocation to the cell membrane15.
This effect peaked at concentrations of 0.25 and 0.5 nM, whereas
higher concentrations led to dampened signal, possibly suggesting
receptor desensitization, a phenomenon typically observed in
GPCR activation16 (Fig. 6a and Supplementary Fig. 5b).
To explore the role of GPR116 in the FcsFNDC4-dependent
effects on insulin-induced pAKT and pAS160, we employed an
antibody, targeting the extracellular part of GPR116 (anti-GPR116)
(ab111169) (Supplementary Fig. 4i, j). This antibody disrupted the
binding of FcsFNDC4 to GPR116 OE HEK293T cells compared to
the isotype control (Fig. 4k). Upon O/N exposure to insulin,
FcsFNDC4 did not improve insulin sensitivity in the presence of
anti-GPR116 antibody as it failed to enhance insulin-induced pAKT
and pAS160 levels (Fig. 6b and Supplementary Fig. 5b). In addition,
to exclude secondary effects of the chronic incubation, we pre-
incubated healthy 3T3L1 adipocytes with GPR116-blocking anti-
body for 30min prior to the addition of fresh media containing
only FcsFNDC4 and insulin for 5min. Also under these acute
conditions, FcsFNDC4 enhanced insulin-induced pAKT levels;
however, it failed to do so in adipocytes pre-incubated with anti-
GPR116 antibody (Supplementary Fig. 5c). Importantly, under both
chronic and acute conditions, FcsFNDC4–GPR116 interaction
enhanced pAKT and pAS160 levels only in combination with
insulin, supporting the notion that FNDC4–GPR116 does not
signal directly on pAKT (Supplementary Fig. 5c, d), but acts as a
necessary insulin sensitizer in WAT. Previously, it has been
published that sFNDC4 promotes insulin signaling via the AMPK-
HO-1 pathway in adipocytes6 and to also activate pSTAT3 in
macrophages4. Therefore, we also assessed the direct effects of
sFNDC4–GPR116 on pAMPK, HO-1, and pSTAT3 levels in
mature adipocytes. We found no changes in pAMPK (Supplemen-
tary Fig. 5e), HO-1, or pSTAT3 upon incubation of mature
adipocytes with different concentrations of FcsFNDC4 for 15 or 30
min (Supplementary Fig. 5f). Of note FcsFNDC4 demonstrated
GPR116-dependent activation of pERK1/2, which is a common end
point of insulin receptor activation signaling and activation readout
for many GPCRs (Supplementary Fig. 5d), supporting the existence
of cross-talk between the sFNDC4–GPR116 and the insulin
receptor signaling.
One of the functional consequences of enhanced insulin
signaling in white adipocytes is the promotion of insulin-
stimulated glucose uptake via the GLUT4 transporter15. To
investigate the role of the sFNDC4–GPR116 interaction in
insulin-stimulated glucose uptake in 3T3L1 mature adipocytes,
we assessed direct glucose uptake using [3H]2-deoxyglucose
(3H-2DG). Under the above-described conditions of insulin
resistance in 3T3L1 mature adipocytes, FcsFNDC4 promoted
insulin-stimulated glucose uptake, which was absent in the
presence of anti-GPR116 antibody (Fig. 6c). Overall, these
findings underscored a functional dependence of FcsFNDC4 on
GPR116 and they suggested that the interaction of FcsFNDC4
with GPR116 was required for exerting its insulin-sensitizing
effects in white adipocytes.
Interaction of FcsFNDC4 and GPR116 N-terminus induces Gs-
cAMP signaling in adipocytes. To investigate whether
FcsFNDC4 triggered a typical G protein signaling via GPR116, we
employed a luciferase reporter assay for G protein coupling. To
that end, we generated hygromycin-resistant 3T3L1 fibroblast
clonal cell lines, each carrying stable expression of transcription
reporters: CRE-lu2P, cAMP response element (reporting for Gs
signaling), NFAT-RE luc2P, nuclear factor of activated T-cells
response element (reporting for Gq signaling), SRE-luc2P, serum
response element (reporting Gai signaling), and SRF-luc2P,
serum response factor response element (reporting for
G12/13 signaling)17. On day 8 post adipogenic differentiation of
each of the above reporter cell lines into mature adipocytes, we
performed dose stimulation with FcsFNDC4 or Fc control. We
observed dose-dependent increase in CRE-luc2P activity 3–4 h
post induction, whereas Fc control did not induce any increase in
luminescence. We did not observe any change in luminescence in
none of the NFAT-RE (16 h post induction), SRE (3–4 h post
induction), or SRF (3–4 h post induction) reporter carrying adi-
pocytes (Fig. 6d). As a positive control for the assay functionality,
we used Forskolin 10 μM for the CRE-luc2P activity, 40% fetal
bovine serum (FBS)+ 20 ng/ml phorbol 12-myristate 13-acetate
(PMA) for the SRE-luc2P activity and 40% FBS for the SRF-luc2P
activity. For those reporters, the positive control induction
resulted in a significant increase in luminescence compared to
control media condition already at 3–4 h post induction; however,
the induction of the NFAT-RE luc2P activity by ionomycin
1 μM+ PMA 10 ng/ml required 16 h to produce a significant
difference in luminescence compared to the control media.
Nevertheless, stimulation with FcFNDC4 did not induce NFAT-
RE luc2P activity neither after 16 h of incubation (Fig. 6d) nor
after 3–4 h of stimulation (16 h stimulation is shown in Fig. 6d).
These findings suggest that sFNDC4 triggers an early Gs-cAMP
signaling in white adipocytes, which is consistent with the idea of
targeting a GPCR receptor. To assess the dependence of this
signaling on the interaction of FcsFNDC4 to GPR116 ectodo-
main, we performed the same dose induction in the CRE-luc2P
3T3L1 adipocytes, which were incubated with the anti-GPR116
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antibody, or isotype control 30 min prior stimulation with
FcsFNDC4. The presence of anti-GPR116 antibody inhibited the
FcsFNDC4-induced CRE-luc2P activity, whereas FcsFNDC4
indeed induced CRE-luc2P activity in isotype control-treated
adipocytes (Fig. 6e and Supplementary Fig. 5g). The induction of
Gs-cAMP signaling by FcsFNDC4–GPR116 was further sup-
ported by a rapid and transient induction of cAMP-sensitive
pCREB and pPKA substrate in response to FcsFNDC4 (Fig. 6f, g),
which was absent in adipocytes pre-incubated with anti-GPR116
blocking antibody (Fig. 6g). Furthermore, we did not observe
any changes in pPKC substrate, in response to FcsFNDC4
(Supplementary Fig. 5h). Therefore, we concluded that
FcsFNDC4–GPR116 activation in white adipocytes leads to Gs
coupling and activates cAMP signaling.
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The FNDC4–GPR116 axis responds to therapeutic interven-
tions in diabetic mice and humans. Finally, to investigate
whether the FNDC4–GPR116 axis responded to preventive or
therapeutic approaches against T2D, we examined the regulation
of the ligand–receptor system in human cohorts of weight loss
interventions with either bariatric surgery (BS) or diet/exercise
and in mouse models of weight gain prevention using inter-
mittent fasting or caloric restriction (CR). We found that weight
loss due to BS (Fig. 7a, b) or diet/exercise (Fig. 7c, d) led to
increased serum FNDC4 levels in the same patient when com-
pared to serum sFNDC4 levels before the intervention but only in
those individuals who experienced improved insulin sensitivity
after the intervention (after no T2D; Fig. 7a, c). In contrast, serum
sFNDC4 levels were not altered or increased in those individuals
who did not improve in terms of insulin sensitivity after either
intervention (Fig. 7b, d). GPR116 mRNA was also well expressed
in human biopsies of subcutaneous (Subc.WAT) and visceral fat
depots (Visc.WAT). GPR116 was more abundantly found in the
Subc.WAT and its expression levels were affected mainly in this
depot, dropping dramatically in obese subjects with IGT and IIT
as well as obese with T2D (Fig. 7e). Furthermore, in fat biopsies
from humans who underwent BS for weight loss, we observed,
similarly to serum sFNDC4, that GPR116 mRNA levels increased
after the intervention in the SC fat and showed no difference for
the visceral fat (Fig. 7f, g).
Intermittent fasting and CR have been proposed as preventive
dietary patterns against insulin resistance and effective weight loss
methods. Intriguingly, liver mRNA levels of Fndc4 (Fig. 7h) and
gWAT Gpr116 (Fig. 7i) as well as plasma levels of sFNDC4
(Fig. 7j) increased in mice that underwent intermittent fasting or
CR compared to the ad libitum HFD-fed mice. Thus, the
ligand–receptor system FNDC4–GPR116 responded to therapeu-
tic interventions against T2D, closely correlating with the
intervention-based improvements in insulin sensitivity and body
weight in both mice and human patients.
Discussion
Here, we describe an endocrine axis and its implications in pre-
diabetes. We provide evidence that FNDC4 acts as an endocrine
factor, which controls systemic glucose tolerance and responds to
insulin-sensitizing treatments such as diet, exercise, or BS in
conjunction with the reversal of T2D and improvements in
insulin resistance in mice and humans. Importantly, our data
provide evidence that sFNDC4 acts as a hepatokine, as we
observed that lowering of liver FNDC4 mRNA led to corre-
sponding lowering of the sFNDC4-circulating levels in mice.
Remarkably, we show that just 30% reduction of liver and cir-
culating levels of sFNDC4 can lead to pre-diabetes manifesta-
tions, such as glucose intolerance and compensatory
hyperinsulinemia. Currently, pre-diabetes in humans is targeted
mainly by prescription of metformin and promotion of lifestyle
changes, such as diet/exercise. However, despite those interven-
tions many patients progress to full-blown T2D suggesting the
existence of unmanaged factors. We now demonstrate here that
sFNDC4 circulates in human blood and its levels negatively
correlate with insulin resistance. Our data suggest that sFNDC4
levels respond very quickly to diabetogenic lifestyles, such as
HFD, and do recover by successful insulin-sensitizing therapies,
such as diet/exercise or BS. Although in our paired serum samples
of humans exposed to HFD we observed only a 10% decrease in
the circulating levels of sFNDC4, our mouse studies support that
a massive drop of sFNDC4-circulating levels is not necessary to
lead to pre-diabetic phenotypes. Importantly, therapeutic injec-
tions of long-lived human FcsFNDC4 effectively managed glucose
intolerance in mice, providing a prototype pharmacological
protein, which now is up for further optimization in future
clinical trials.
The identification of the sFNDC4 receptor is a key information
with respect to the in vivo mode of action of sFNDC4. Interestingly,
we observed that therapeutic injections of FcsFNDC4 specifically
promoted glucose uptake and insulin signaling in the WAT upon
HFD. We identified the up-to-date orphan GPR116 to be a func-
tional receptor of sFNDC4 in vitro and in vivo. Supporting the
notion that FcsFNDC4 primarily targets the WAT via GPR116,
FcsFNDC4 failed to improve glucose tolerance in mice lacking
GPR116 specifically in AT. It is intriguing that, despite the wide
expression of GPR116 in metabolic tissues, such as muscle and liver,
FcsFNDC4 effects were mediated exclusively by AT GPR116. Based
on the analysis of mouse tissue-specific RNA-seq data, a recent
study has predicted at least 19 putative isoforms for GPR11618.
Thus, a possible explanation, which requires experimental con-
firmation, could be that interaction of sFNDC4 with specific
receptor isoforms may mediate the tissue-specific effects of this
hormone. Most importantly, future work will focus on clarifying the
relevance of human GPR116 isoforms on sFNDC4 signaling.
GPR116 is a typical member of the adhesion GPCRs family,
which possess a long extracellular N terminal fragement (NTF).
The NTF is self cleaved and can modulate the baseline activity of
Fig. 6 sFNDC4 insulin-sensitizing effects in 3T3L1 adipocytes require interaction with GPR116 and involve Gs-cAMP signaling. a WB of the indicated
proteins: overnight incubation (O/N—16 h) of 3T3L1 adipocytes with FcsFNDC4 (FcsF4) or Fc with 10 nM of insulin or without insulin (w/o). Following
O/N incubations, the cells were serum starved for 3 h. After that, cells were stimulated with insulin at the indicated concentrations (0, 0.5, 1 nM) for 5 min.
b WB of the indicated proteins: 3T3L1 adipocytes were treated overnight with insulin (10 nM) or w/o and FcsFNDC4 or Fc in the presence of antiGPR116
(ab111169) (0.4 µg/ml) or isotype control (0.4 µg/ml). Prior acute insulin stimulation for 5 min, cells were incubated in serum-free media (SFM) for 3 h. For
a, b, this experiment was performed at least two times and experiment repeats are shown in Supplementary Fig. 5 and quantification of blots in
Supplementary Fig. 6. c Tritium-labeled glucose uptake at the indicated conditions. Cells were treated as in b and, after serum starvation, were stimulated
with 1 nM insulin for 20min and glucose transport was initiated by the addition of 3H-2DG (PerkinElmer Life Sciences) (0.25 μCi/well, 50 μM unlabeled 2-
deoxyglucose) for 5min, when the experiment was terminated. n= 3 replicate wells of a representative experiment out of two experiments is shown. d, e
Stimulation of 3T3L1 adipocytes luciferase reporter stable cells lines with the indicated concentrations of stimuli. Stimulation was 3–4 h for the CRE-, SRE-,
and SRF-luc2P cell lines and 16 h for the NFAT-RE luc2P cell line. For e, antiGPR116 (ab111169) 0.4 μg/ml was added 30min prior the addition of the rec.
proteins then media was removed and replaced with media containing the indicated concentrations of rec. proteins. In d, n= 3 replicate wells and NFAT
control n= 6 replicate wells of a representative experiment out of at least 3 independent experiments is shown. In e, n= 4 independent experiments. f WB:
3T3L1 adipocytes and g WB: adipocytes derived from mouse primary SVF cells were incubated in SFM for 3 h and then stimulated in SMF with the indicated
dose of rec. protein or antiGPR116 antibody 0.4 μg/ml for g and for the indicated duration of incubation (min). For d, f, g, at least three independent
experiments were performed. In d, e, phosphodiesterase (PDE) inhibitor, IBMX (0,5mM), was present in the media during the treatment of Cre2LucP
adipocytes, whereas in f, g no phosphodiesterase (PDE) inhibitors were present. In c–e, bars are mean ± SEM and statistics represents Student’s unpaired
two-tailed t test. p p-value, ns non-significant, NT non-treated. Phospho-antibodies: pAKTSer473, pCREBSer133, pAS160Thr642. Source data are provided as a
Source data file.
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Fig. 7 FNDC4–GPR116 axis response to anti-diabetic interventions in humans and mice positively correlates with improvements in insulin sensitivity
after the intervention. Quantification of serum sFNDC4 protein in paired samples of individuals who underwent weight loss intervention by bariatric
surgery (BS) a (n= 26 humans), b (n= 14 humans), or c (n= 24 humans), d (n= 23 humans) diet and exercise. Statistics represent paired two-tailed t
test. e–g RT-qPCR quantification of GPR116 mRNA at the indicated groups. ND non-diabetic, T2D type 2 diabetes, Obese-IGT/IIT: impaired glucose
tolerance/insulin tolerance (cross-sectional study Leipzig), BS bariatric surgery. n= human and the number of individuals is indicated on the graphs. For e,
an unpaired two-tailed t test was used. For f, g, a paired two-tailed t test was used. h, i RT-qPCR quantification of Fndc4 and Gpr116 at the indicated tissues
in mice ad libitum (AL), intermittent fasting (IF), or chow and HFD (45% fat) diet and caloric restriction (CR) upon HFD (45% fat). j Quantification of
plasma sFNDC4 ng/ml at the indicated groups. Blood was collected from the central vein after decapitation (trunk). For h–j, n=mice and the exact number
of mice per group is shown on the graphs. Statistics represent an unpaired two-tailed t test. In e, h–j, bars represent mean ± SEM. a–d and f, g: subjects’
information are shown in Supplementary Table 2. For subjects’ information related to e, see Supplementary Table 1. Source data are provided as a Source
data file.
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adhesion GPCRs by (a) parts of it being non-covalently associated
with the extracellular interface of the 7TM part of the remaining
GPCR, after NTF cleavage and (b) by interacting with other
adjacent membrane or extracellular matrix proteins19. Signaling
via the NTF of adhesion GPCRs is complex and not well
understood. The current leading model of adhesion GPCRs
activation is that post NTF removal, the remaing membrane
bound C-terminal fragment (CTF) exposes a peptide agonist
(tethered peptide), which activates the receptor in an orthosteric
agonism manner to initiate interactions with heterotrimeric G
proteins. NTF signaling has been shown in certain cases to act
autonomously or to interplay with the CTF to initiate or not
heterotrimeric G protein signaling20. Due to these properties,
NTF may provide spatiotemporal and context-specific signaling
properties to its receptor. Specifically for GPR116, it has been
shown that NTF removal triggers Gq signaling and calcium
mobilization via tethered peptide agonism in alveolar type II
(AT2) cells21. However, signaling via hormone binding to the
NTF-GPR116 is completely unknown. In our study, we found
that sFNDC4 specifically and strongly interacted with the NTF-
GPR116 and we provide evidence that this interaction led to
cross-talk with the insulin signaling pathway in adipocytes, which
has been shown in the past to be one mechanism via which
GPCRs may affect insulin action22. Based on specific Cre-
dependent reporter gene activation and Gs-cAMP signaling, such
as pCREB and pPKA substrate, we claim that sFNDC4 via
interaction with GPR116 stimulates Gs and cAMP as secondary
messenger in adipocytes. Furthermore, the lack of effect of
sFNDC4 on the pPKC substrate levels suggested the absence of
induction of parallel Gs and Gq signaling and restricted the
sFNDC4–GPR116 interaction to a specific Gs-cAMP signaling
pathway in white adipocytes. Typically, Gs coupling has been
linked to increased lipolysis, mitochondrial oxidation, and
browning in white adipocytes23. In our study, we did not find any
effect of FcsFNDC4 (produced in mammalian cells and as such
being free of endotoxin) or native sFNDC4 (produced in Escher-
ichia coli) on browning and mitochondrial genes of mouse pri-
mary adipocytes (Supplementary Fig. 7a) nor changes in EE after
long term or acute injections of FcsFNDC4 to mice. However,
opposite to potent inducers of cAMP signaling, such as iso-
proterenol, sFNDC4 demonstrated a rapid and transient increase
in cAMP targets (pCREB, pPKA substrate). Earlier studies have
highlighted the importance of acute, transient, or partial
cAMP stimulation for Glut4-dependent glucose uptake24–26,
which is in line with the observed stimulatory effects of the
FNDC4–GPR116 axis on adipocyte glucose uptake. It is tempting to
speculate about the potential intersection nodes between the
FNDC4–GPR116–cAMP and the insulin–Akt pathway. Prime
candidate tracks to explore will be the AS160 signaling nodule27,
as well as a direct PKA-mediated Akt activation via physical con-
tacts as shown in endothelial cells during late ischemic
preconditioning28. Overall, the present study provides a paradigm
on the mode of GPR116 activation and sheds light on the metabolic
implications of the NTF-GPR116 in AT.
According to a previous mouse model of GPR116 deletion
under the control of the Ap2Cre promoter, it has been suggested
that GPR116 deletion in the AT results in systemic insulin
resistance and ectopic fat accumulation29. The lack of specificity
of the Ap2 gene expression for the adipocytes30 prompted us to
employ the Adiponectin Cre promoter to drive deletion of
GPR116 in mature adipocytes. We have observed loss of the
FcsFNDC4 insulin-sensitizing effects in the GPR116Ad−/− mice.
These findings further support specific functional dependency of
these two molecules also in vivo and clearly draw a liver-to-WAT
endocrine axis in the control of glucose homeostasis. Furthermore,
GPR116Ad−/− mice exhibited mild pre-diabetes symptoms, such
as compensatory hyperinsulinemia compared to GPR116Adf/f lit-
termates, but these phenotypes were milder compared to those
observed upon deletion of GPR116 under the control of the Ap2
promoter (Ap2CreGPR116−/− mouse). These observations may
suggest that another cell type outside the adipocyte may be
responsible for the severe effects of GPR116 deletion on glucose
homeostasis, possibly occurring at early developmental stages.
In contrast to the low therapeutic dose of FcsFNDC4 (0.2mg/kg)
required for improvement in glucose tolerance in HFD mice in
our current study, a much higher dose (3 mg/kg) has been pre-
viously utilized to treat inflammation in a mouse model of colitis4
as well as to improve hyperlipidemia ER stress-induced insulin
resistance on HFD fed mice, the later treated daily with Escher-
ichia coli-produced native sFNDC46. Of note, in our pilot work
the dose of 3 mg/kg of FcsFNDC4 every other day in HFD mice
had no impact on glucose homeostasis or systemic inflammation
(Supplementary Fig. 7b), supporting that the effects of FcsFNDC4
on glucose homeostasis are not secondarily to the improved
inflammation. At a dose of 0.2 mg/kg every other day, we
observed improved glucose tolerance and improved inflamma-
tion, proposing that insulin sensitization in the adipocytes pre-
cedes the anti-inflammatory effects of FcsFNDC4. In addition, we
observed a remarkable decrease of resistin in the circulation and
in the WAT of HFD treated with FcsFNDC4 compared to the
control mice. Resistin is a proinflammatory adipokine, which
several previous studies have shown to be specifically secreted by
white adipocytes in mice8. Due to the fact that resistin levels
decrease as a response to insulin sensitization in adipocytes31,
modulation of FcsFNDC4 levels of resistin as a result of improved
insulin sensitivity provide an explanation of reduced inflamma-
tion in our FcsFNDC4-injected mice secondarily to the beneficial
effects of FcsFNDC4 in white adipocytes. Furthermore, the suf-
ficiently low therapeutic dose by which sFNDC4 exerts metabolic
benefits is consistent with the targeting of a high-affinity receptor
in vivo and suggests that apparently a much higher dose of
sFNDC4 is required to exert its anti-inflammatory effects directly
on macrophages. We have found that GPR116 has almost no
detectable mRNA levels in resident, induced or mouse macro-
phages isolated from the bone marrow, AT macrophages, or
alveolar macrophages32 (raw Ct values: >35), compared to adi-
pocytes (raw Ct values: 25–26). However, injections of FcsFNDC4
in GPR116Ad−/− failed to lower circulating levels of resistin and
TNFalpha, as it was the case for the FcsFNDC4 injections in
GPR116Adf/f mice. These findings strongly support the notion
that the anti-inflammatory effects of FcsFNDC4 in HFD-injected
mice derive via an adipocyte GPR116-dependent mechanism.
Interestingly, our present study suggest that that insulin-
sensitizing mechanisms of sFNDC4-GRP116 do not involve ER
stress or changes in the pAMPK-HO-1 pathway but employ Gs-
cAMP signaling to prime and enhance the action of insulin in
those cells. Thus, our current work clearly provides a conceptual
advance not only in terms of the functions of FcsFNDC4 but also
provide a targeted mechanism by which the liver–AT axis con-
trols systemic glucose homeostasis and inflammation. In addition,
our work suggests the existence of a signaling pathway in mac-
rophages, which is perhaps of much lower specificity compared to
other metabolic cells, such as adipocytes, but may have important
implications for immunomodulation by sFNDC4, for example, in
the case of severe and chronic inflammation, as seen in the
dextran sodium sulfate colitis mouse model4.
In conclusion, the present work uncovers a FNDC4
ligand–GPR116 receptor interaction specifically in WAT, con-
trolling systemic glucose tolerance (Supplementary Fig. 8). Our
findings suggest a potential therapeutic exploitation of the
sFNDC4–GPR116 axis in human pre-diabetes as delivery of
therapeutic recombinant FcsFNDC4 substantially improved
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glucose tolerance in pre-clinical settings in a GPR116-dependent
manner, and the sFNDC4–GPR116 axis is functionally and
mechanistically conserved in humans.
Methods
Animals. All mice (Mus musculus) were housed in a temperature-controlled
(20–22 °C) room on a 12-h light/dark cycle. Mice were fed a chow diet or HFD
research diets (45% fat and 60% fat) where indicated. Chow fed mice were housed
4–5 mice per cage and mice on HFD were housed 3–4 mice per cage. Experiments
were performed in age- and sex-matched mice.
GPR116 KO mice have previously been described by Yang et al.33 and
Fukuzawa et al.34 and carry deletion of exon2, which encodes for the start codon
and signal peptide (SP) of GPR116. GPR116Ad−/− (adiponectinCrexGPR116
flox/flox mice) derived from breedings of the Adiponectin Cre (C57Bl6Jgenetic
background) to GPR116flox/flox (C57BL6N genetic background). They were on a
C57bl6N/J mixed background. In the manuscript, we used male mice 20–22 weeks
old. Littermates of the same sex were randomly assigned to experimental groups.
GPR116flox/flox 33 and Adiponectin-Cre transgenic mice were crossed to produce the
adipose-specific GPR116 conditional KO mice: GPR116Ad−/−, which is Adiponectin
Cre-positive and GPR116 flox/flox mice. Adiponectin Cre-negative GPR116flox/flox
mice were used as controls. Genotyping was done according to Yang et al.33 and the
primers sequences are given in Supplementary Table 3.
WT mice for rec. protein injections, HFDs, and primary cell isolation were
C57BL6N, male mice, 12–25 weeks old, and they were purchased from Charles
River Laboratory. For isolation of primary SVF cells, we used WT mice, 6–7 weeks
old, males, purchased from Charles Rivers Laboratory. For isolation of primary
islets, WT mice, male, 8–13 weeks old, C57Bl6N, from Charles Rivers were used.
For the isolation of primary SVF cells from GPR116 WT, HET, KO mice, the mice
were on a C57Bl6N genetic background, males, 6–7 weeks old.
All experiments were conducted in accordance with European Directive 2010/
63/EU on the protection of animals used for scientific purposes and were
performed with permission from the Animal Care and Use Committee (N169/13,
N412/12, N187/12 and 55.2-1-54-2532-164-2015, 55.2-1-55-2532-49-2017, 55.2-1-
54-2532-125-2017, 55.2-1-54-2532-117-2016).
All mice were kept in mouse animal facility within the institute, under
controlled temperature, light, and air humidity conditions. The rooms where mice
were kept had ambient temperature of 20–22 °C and 46–65% relative humidity,
appropriate for mice, on a 12-h light/dark cycle.
Cell lines. Human embryonic kidney 293 (HEK293) cells were established from
female fetus. NIH3T3 fibroblasts are mouse fibroblasts, which lack adipo-
genic differentiation capacity to mature adipocytes. 3T3L1 are WAT mouse
fibroblasts, with good adipogenic differentiation capacity. HepG2 is a human liver
cancer cell line. All cell lines were cultured in Dulbecco’s Modified Eagle Medium
(DMEM) high glucose media with 10% FBS and 1% penicillin–streptomycin (P/S)
at 37 °C in 5% CO2. Immortalized SVF cells used for FACS-based receptor
screening were derived from male 129SVE mice, as described in refs. 35,9. All cell
lines were purchased from ATCC.
Primary cell cultures. Primary islets were isolated from the pancreas of 8–13-
week-old C57BL/6N mice via collagenase P (Roche) digestion as described before
(Szot et al. 2007)36 followed by a centrifugation step using an Optiprep density
gradient (Sigma). Isolated islets were handpicked twice and incubated O/N in
RPMI supplemented with 10% v/v FBS and 1% v/v PS for recovery.
Study participants—human studies
Cross-sectional study (Leipzig)37. Paired samples of subcutaneous, omental visceral
AT and liver were obtained from 66 individuals (29 women, 37 men). Body Mass
Index (BMI) ranged from 22.7 to 45.6 kg/m2. The study was approved by the Ethics
Committee of the University of Leipzig (approval numbers: 363-10-13122010 159-
12-21052012) and performed in accordance to the declaration of Helsinki. All
subjects gave written informed consent to use their data in anonymized form for
research purposes before taking part in this study. For the study protocol, please see
Wueest et al.37.
Weight loss intervention studies (Leipzig). Paired subcutaneous, omental visceral
AT, and serum samples were further collected from 50 individuals (20 males and
30 females) in the context of a 2-step BS approach as described previously38,39. In
parallel, 50 individuals underwent a combined exercise and diet intervention
program over 12 months. The exercise program included 180 min per week
supervised mixed strength and endurance training and a −500 kcal/day hypoca-
loric diet39.
All AT samples were collected during laparoscopic abdominal surgery as
described previously40. AT was immediately frozen in liquid nitrogen and stored at
−80 °C. The study was approved by the ethics committee of the University of
Leipzig (approval no: 159-12-21052012) and performed in accordance to the
declaration of Helsinki. All subjects gave written informed consent before taking
part in this study. For study protocol, please see Kannt et al.39 and Schmitz et al.38.
The categorization of patients to T2D and no T2D after the end of the
intervention was done based on the following criteria: the requirement of anti-
diabetic medications, hemoglobin A1c (HbA1c) <6%, and fasting plasma glucose
<6.0 mmol/l.
Measurement of body composition and metabolic parameters (Leipzig). BMI was
calculated by weight (kg) divided by square of height (m). Weight-to-height ratio
was calculated from the measured waist and hip circumference. Computed
tomography or magnetic resonance imaging scans at level L4/5 were used to cal-
culate abdominal SC and visceral fat area (cm2) and dual-energy X-ray absorp-
tiometry or bioimpedance analyses to measure body fat content (%). In a subgroup,
insulin sensitivity was quantified with the glucose infusion rate during an
euglycemic–hyperinsulinemic clamp as described40,41. All baseline blood samples
were collected between 8 and 10 a.m. after an O/N fast. Plasma insulin was
measured with an enzyme immunometric assay for the IMMULITE automated
analyzer (Diagnostic Products Corporation, Los Angeles, CA, USA). Plasma glu-
cose, HbA1c, high-density lipoprotein-cholesterol, low-density lipoprotein-cho-
lesterol, free fatty acids, and TG were measured in an automated analyzer (Cobas
8000, Roche Diagnostics, Mannheim, Germany). Serum adiponectin was measured
and mean subcutaneous and visceral adipocyte size was determined as previously
described in Klöting et al.40. For subjects’ information, see Supplementary Table S2.
Analysis of FNDC4 and GPR116 mRNA expression in human tissues. RNA from
AT was extracted by using the RNeasy Lipid Tissue Mini Kit (Qiagen, Hilden,
Germany). Quantity and integrity of RNA was monitored with NanoVue plus
Spectrophotometer (GE Healthcare, Freiburg, Germany). One microgram of total
RNA from subcutaneous and visceral AT and liver were reverse-transcribed with
standard reagents (Life Technologies, Darmstadt, Germany). cDNA was then
processed for TaqMan probe-based quantitative real-time polymerase chain reac-
tion (qPCR) using the QuantStudio 6 Flex Real-Time PCR System (Life Tech-
nologies, Darmstadt, Germany). Expression of FNDC4 and GPR116 were calculated
by the standard curve method and normalized to the expression of 18S rRNA
(housekeeping transcript). The probes (Life Technologies, Darmstadt, Germany)
for FNDC4 (Hs01100278_g1) GPR116 (Hs00391810_m1), and 18S rRNA
(Hs99999901_s1) span exon–exon boundaries to improve the specificity of the
qPCR. For subjects’ information, see also Supplementary Tables S1 and S2.
NUtrigenomics analysis in Twins (NUGAT) study (DIfE). The current human
cohort included 92 healthy, non-obese subjects, 34 males and 58 females (46 pairs
of twins—34 monozygotic and 12 dizygotic). The age ranged from 18 to 70 years
with a median of 25 years. Only twins with a BMI=weight [kg]/height [m] ×
height [m] between 18 and 30 kg/m2 were included. The dietary intervention was
carried out in a sequential design and under isocaloric conditions. Individual
energy requirements were calculated based on participants resting EE determined
by indirect calorimetry and physical activity level assessed by questionnaire. Par-
ticipants were standardized for their nutritional behavior prior to the study via a 6-
week carbohydrate-rich low-fat diet (LF, 55% carbohydrate, 30% fat, 15% protein)
before they switched to a 6-week HFD (40% carbohydrate, 45% fat, 15% protein)
with emphasis on foods high in saturated fat42. Participants were given intensive,
regular, and detailed dietary guidance by a nutritionist over the entire period of
intervention to ensure compliance. During HFD intervention fasting glucose values
and glucose tolerance were assessed by intravenous (iv) GTT as well as fasting
insulin values and HOMA—insulin resistance.
The detailed study protocol has first time described in Pivovarova et al.42.The
Pivovarova et al.42 paper is on a subgroup of NUGAT study, the latest including in
a total of 92 participants. All 92 individuals7,43–45 of the NUGAT study have been
analyzed in the present manuscript and detailed information on those subjects can
be found in Frahnow et al.43, Schüler et al.7,44, and Schüler et al45. Exclusion
criteria were consumptive diseases, diabetes mellitus, high-grade anemia, renal
failure, moderate-to-severe heart diseases, angina pectoris, or stroke in the past
6 months, food allergy, eating disorders, body weight change ≥3 kg within
3 months prior to the study, pregnancy or breastfeeding, drugs influencing
metabolic homeostasis, lipid and liver metabolism, or inflammation (e.g., systemic
corticosteroids). Participants were initially screened to determine their eligibility
for enrollment in the intervention study. This screening visit comprised physical
examination, medical history, anthropometric measurements, and blood analysis.
Additionally, a standardized 3-h, 75-g OGTT was performed. The study was
approved by the Ethics Commission of Charité University Medicine Berlin. The
study was conducted in the outpatient department of German Institute of Human
Nutrition in accordance with the Declaration of Helsinki and registered at www.
clinicaltrials.gov (NCT01631123). All subjects provided written, informed consent.
Expression and purification of recombinant proteins. FcsFNDC4 generation:
6xHis-Fc-sFNDC4 (FcsFNDC4) fusion protein and 6xHis-Fc (Fc) control were
expressed using a pEFIRES expression vector. DNA fragment coding SP from
Fndc5 fused to 6xHis-Fc was synthesized by GeneScript USA Inc. and cloned into
pEFIRES modified multiple cloning site, using NheI and NotI restriction sites. The
extracellular part of FNDC4 (sFNDC4) was PCR-amplified using mouse clone
MR223815 (OriGene) as a template with the set of primers: forward—GAGAGC
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GGCCGCTCGACCTCCCTCTCCTGTG, reverse—GAGAGAATTCATTCCCCT
GTCTGCAATGGC. The amplified sFNDC4 fragment was cloned into a SP-6xHis-
Fc-pEFIRES vector using NotI and EcoRI restriction sites to produce SP-6xHis-
hFc-sFNDC4-pEFIRES expression constructs, respectively. In addition, a linker
was added in between the hFc sequence and the sFNDC4 sequence: ENLTFQGAA.







GLRGESPPGPRVHFRTLK GSDRLPSNSSSPGDITVEGLDGERPLQTGE, with SP
sequence: MPPGPCAWPPRAALRLWLGCVCFALVQAD. This construct was
transfected to CHO-S cells and stable cell lines were selected using puromycin as a
selection agent. For protein production, stable CHO-S suspension cultures were
grown in OptiCHO medium (Life Technologies) supplemented with Ala-Glu
(Sigma). Culture supernatants were loaded onto HisTrap Excel columns (GE
Healthcare) in 5 mM imidazole containing Column loading buffer (1 M NaCl) with
protease inhibitors, pH 7.4, washed with 5 and 20 mM imidazole containing wash
buffers (0.2 M NaCl, 0.02 M NaHPO4, pH 7.4) and eluted with 250 mM imidazole
elution buffer (0.2 M NaCl, 0.02M NaHPO4, pH 7.4). Eluted protein was dialyzed
against phosphate-buffered saline (PBS) buffer. Newly synthesized proteins were
concentrated using 3 kDa Amicon Ultra-15 centrifugal units (Merck Millipore) to
1 mg/ml and snap frozen prior to the analysis. In all, 0.5 ml of the protein sample
was loaded onto Superdex 10/300 GL (GE Healthcare) equilibrated in PBS buffer.
Superdex 10/300 GL was calibrated using the High Molecular Weight (HMW) Kit
(GE Healthcare).
Non-Fc-fused FNDC4. FNDC4 (aa40-160, UniProtKB-Q3TR08 Mouse FNDC4)
was cloned into a pETM11 vector for bacterial expression. After expression of 1 L
in TB medium, induction with IPTG and O/N growth at 20 °C, cells were collected
and frozen at −80 °C until further usage. Cells were lysed in 20 mM Tris pH 8.5,
150 mM NaCl, 10 mM imidazole, 5% glycerol, and 2 mM β-mercaptoethanol and
supplemented with protease inhibitor. Prior to sonication and lysate clearance by
45 min centrifugation, at 25,000 rpm, supernatant was applied to a prepacked
nickel column. After washing with 20 times column volume, protein was eluted in
an imidazole gradient to a final concentration of 350 mM imidazole. The His-tag
version of FNDC4 was then further purified over a size exclusion chromatography
column S200, whereas untagged FNDC4 was first supplemented with TEV pro-
tease, to cleave the His-tag when simultaneously dialyzed O/N against a buffer with
10 mM imidazole. Prior to gel filtration, cleaved FNDC4 domain was subjected to a
nickel column to remove non-cleaved His-tag FNDC4 and His-tagged TEV pro-
tease. In both cases, the final buffer used was 10 mM Hepes, 100 mM NaCl, 5%
glycerol, and 1 mM β-mercaptoethanol. Untagged FNDC4 used for the FACS
binding competition assays in PBS buffer. For cell treatment experiments (islets,
adipocytes), sFNDC4 (untagged) from Adipogen was used (cat.no AG-40B-0124).
Transient OE of human RXFP1, ITGAD, and human GPR116. Open reading
frames for human RXFP1 (RC511338), ITGAD (RC224758), and human GPR116
(RC209170) were purchased from OriGene and subcloned into pENTR-CMV
vector (Gateway Invitrogen). The plasmids were transfected with lipofectamine
into HEK293 cells with the standard protocol. These cells were used for experi-
ments 48 h post transfection.
FACS binding assay and sorting. The cells were detached by 1-min incubation in
prewarmed 0.05% trypsin EDTA and additionally scraped or only scraped in ice-
cold PBS. Cells were washed three times and suspended in FACS buffer (PBS with
3% FBS), by in between pelleting using centrifugation at 1000 × g for 5 min at 4 °C.
All steps were performed on ice and in the cold room. Fc block (1:200) was added
for 20 min in FACS buffer. Recombinant proteins were then added and incubated
with cells at 4 °C for 40 min, washed three times with cold FACS buffer, followed
by 40-min incubation (4 °C) with anti-human IgG secondary antibody conjugated
with PE (Invitrogen, H10104, 1:200). After the incubation with secondary antibody,
cells were washed twice with FACS buffer and then analyzed by analytical FACS.
Quantification was performed using the mean PE value within the total cell
population (10,000 events were recorded). Measurements of fluorescein iso-
thiocyanate (FITC) values were acquired to correct for cell autofluorescence. For
sorting, the cells were labeled as described above and sorted for high or low mean
PE and normalized to mean FITC (background fluorescence). The incubation with
recombinant proteins was performed in 96-well plates with round bottom. In all,
100,000–300,000 cells were used. During incubation, cells were mixed twice by
gentle vortexing. During washes, a table centrifuge for plates was used at 600 × g for
2 min at 4 °C.
FACS binding in the presence of EDTA. The cells were detached by 1 min
incubation in prewarmed 0.05% trypsin EDTA and additionally scraped in ice-cold
PBS. Cells were washed three times in Krebs–Ringer buffer with the following
composition: 100 mM NaCl, 5 mM KCl, 0.1 mM MgSO4, 0.1 mM CaCl2 0.4 mM
K2HPO4, 10 mM HEPES. All steps were performed in cold. Fc block (1:200) was
added for 20 min in FACS buffer and suspended. FcsFNDC4 was added at 100 nM
final concentration and increasing amount of EDTA (0–10 mM). The rest of the
binding protocol was performed as described above, see “FACS binding assay and
sorting.”
FcsFNDC4 cell binding assay after blocking with anti-GPR116 antibody.
HEK239T cells stably overexpressing human GPR116 were detached in ice-cold
PBS by scraping and pelleted by centrifugation at 1000 × g 5 min at 4 °C and
resuspended in FACS buffer (PBS with 3% FBS). Cells were incubated 20 min with
Fc block on ice, followed by 30-min incubation with antiGPR116 or IgG isotype
control at different concentrations. Antibody was removed by centrifugation at
600 × g for 2 min and then 100 nM of FcsFNDC4 or Fc rec. protein were added on
the cells in FACS buffer for 40 min on ice. Afterwards, cells were washed 3 times
with FACS buffer at 600 × g for 2 min at 4 °C. Anti-human IgG secondary antibody
conjugated with PE (Invitrogen, H10104, 1:200) was added for 40 min incubation
(4 °C). Final two washes with FACS buffer and centrifugation at 600 × g for 2 min
at 4 °C were performed in order to remove excess PE-conjugated antibody.
Transcriptomics. For identifying differentially expressed genes between HBC and
LBC, Affymetrix mouse Chips 2.0St arrays were performed in HBC and LBC and
differentially expressed genes were selected based on p value <0.05, calculated using
Student’s t test and false discovery rate analysis. Three technical replicates were
used and genes were selected on the basis of mean probe intensity >100 in both
groups. Affymetrix global gene expression analysis from sorted LBC and HBC was
performed in the BEA core facility at the Karolinska Institute. Microarray data are
available in GEO (gene expression omnibus) under the number: GSE165329.
GPR116–FNDC4-binding experiments
Pull down. In all, 30 µg of 6xHisFcsFNDC4 or 6xHisFc was bound to 2 mg of
anti6xHis Dynabeads (Invitrogen) for 25 min at room temperature (RT), under
rotation, in 1× binding buffer/wash buffer prepared according to the supplier’s
protocol. Supernatant was collected and the beads were washed 4× for 2 min each
wash, under rotation with 1× binding/wash buffer. Α 100-cm2 dish, with confluent
NIH3T3 cells was lysed in 1× pull-down buffer (as described by the supplier)
supplemented with 1% TritonX-100. Cells were scraped and passed through a 25-G
syringe 10 times and a 27-G syringe for an additional 10 times, on ice. Finally, cell
lysates were sonicated 2× for 10 min at 4 °C in a water bath sonicator and the
supernatant was collected after 10-min centrifugation at 10,000 rpm, 4 °C. Protein
was quantified by the BCA Pierce Assay Kit (Invitrogen), and 300 µg of supernatant
was added on recombinant protein pre-bound beads for 30 min at RT. The
supernatant containing un-precipitated proteins was collected and beads were
washed 4× for 2 min each time, under rotation with 1× binding/wash buffer.
Immunoprecipitated proteins were eluted in 100 µl His elution buffer, as described
by the supplier, for 15 min, at RT, under vigorous shaking. Samples were reduced
in β-mercaptoethanol containing sample buffer and boiled (98 °C) for 7 min. Ten
microliters from each sample was loaded on 7.5% TGX premade mini gel from
BIO-RAD, and protein was transferred to a polyvinylidene difluoride (PVDF)
membrane with semi-dry transfer, under constant voltage of 10 V for 30 min, using
the Trans-Blot Turbo transfer system from BIO-RAD. Membranes were blotted
against anti-GPR116, using the anti-GPR116 antibody ab136262, from Abcam.
Lentivirus packaging, infection, and stable HEK293 clone cell selection. The
lentivirus-based expression vector was also constructed using the Gateway system
(Invitrogen). Human GPR116 with a C terminal FLAG tag was recombined to
plenti6/V5 DEST vector from the pEntry1a GPR116 plasmid. The purified plasmid
was then transfected to HEK293FT cells together with packaging plasmids from
Invitrogen (ViraPower™ Lentiviral Packaging Mix). Seventy-two hours later, the
supernatant of the transfected cells containing lentiviral particles was harvested and
was used to infect new cells. Seventy-two hours after infection with lentivirus
particles, cells were exposed to blasticidin (Invitrogen) for stable selection. Medium
was changed every 3 days with fresh blasticidin. Two weeks later, the cells were
trypsinized and re-suspended as single-cell suspension into 96-well plates. There-
after, single-cell clones were amplified.
Construction of shGpr116 lentivirus and transduction of pre-adipocytes and
adipocytes. Short hairpin RNA (shRNA) lentiviral plasmids (pGFP-C-shlenti)
against mouse Gpr116 were purchased from Origene (CAT#: TL517926), and four
29mer shRNA sequences were used for silencing mouse Gpr116 TL517926A
(TL517926A) 5’-tactccattcacaccactgtcatcaacaa-3’ (SEQ ID NO.: 13), TL517926B
(TL517926B) 5’-tcgcagtgttctgccacttcaccaatgca-3’ (SEQ ID NO.: 14), TL517926C
(TL517926C) 5’-cgtcatcttagacaagtctgccttgaact-3’ (SEQ ID NO.: 12), and
TL517926D (TL517926D) 5’-tgtggctggtgctatccacgacggtcgct-3’ (SEQ ID NO.: 15),
and a non-effective 29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector,
(CAT#: TR30021) 5’-gcactaccagagctaactcagatagtact-3’ (SEQ ID NO.: 16) was used
as a control. For virus production, shRNA lenti vectors were cotransfected O/N,
with packaging plasmids psPAX2 (Addgene) and PMD2.G (Addgene) to
HEK293FT cells, using Lipofectamine 3000. Twenty-four hours later, media was
changed by DMEM 10% FBS containing 1% BSA. After 24 h, the supernatant was
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recovered, filtered with 0.45 mm filters, and used to infect differentiated mature
primary adipocytes. One milliliter of the supernatant was added in 1 well of a 12-
well plate for 24 h. After that, the media was changed to complete DMEM media.
GPR116 mRNA levels were more than 70% deleted, compared to the scrambled
control and it was achieved as early as 72 h post infection.
Reporter luciferase gene assays on 3T3L1 stable reporter cell lines. CRE-,
NFAT-RE, SRE-, and SRF-luc2P transcription activity luciferase reporters from
Promega, cat. no. E8471, E8481, E1340, and E1350, respectively, were transfected
with Lipofectamine 3000 to 3T3L1 fibroblasts (passage 12). Seventy-two hours post
transfection, the media was changed into media with 200μg/ml hygromycin B
(Invitrogen cat. no 10687010) and they were selected for 10–12 days. Clonal cell
lines were generated with the limited dilution method. Media was DMEM+ 10%
FBS+ 1% P/S+ 200 ng/ml hygromycin B and was refreshed every 2 days. For the
experiments, cells were differentiated into mature adipocytes with the protocol
described before46. After the stimulation as described in the main text, cells were
lysed with 1× Reporter lysis buffer—Promega cat. no. E3971, and luminescence was
read after the addition 1:1 of Steady-Glo® Luciferase Assay System – Promega cat.
no. E2520 with the Varioscan Lux plate reader, in a white 96-well plate.
Experiments were performed at day 8 post differentiation. For the CRE-, SRE-,
and SRF-luc2P, prior to stimulation with recombinant FcsFNDC4 and Fc, the
adipocytes were serum starved in DMEM high glucose for 4–5 h. Stimulation was
performed in serum-free conditions for additional 3–4 h. For the CRE-luc2P, all
conditions included 0.5 mM 3-isobutyl-1-methylxanthine (IBMX) (Sigma: I5879).
For the NFAT-RE luc2P, stimulation was performed in 10% FBS+DMEM high
glucose for 16 h. As positive controls for assay functionality, the following were
used: Forskolin 10 µM (Cay11018-1, Biomol), ionomycin 1 µM (sc-3592, Santa
Cruz), and PMA 10–20 ng/ml.
For the stimulation of Cre–luc2P reporter adipocytes, phosphodiesterase
inhibitor IBMX (0.5 mM) was present during the stimulation with rec. proteins or
Foskolin.
In vivo insulin signaling studies. On HFD-fed mice: Mice were fasted O/N
(12–16 h) and subsequently were injected (ip) with 5 U/kg Humulin and organs
were excised after 8 min and snapped frozen in liquid nitrogen.
AAV knockdown in mice. AAV8-U6-GFP-scrmb-shRNA and AAV8-U6-GFP-
shFNDC4 were purchased from Vector Biolabs and injected iv. to 9–10-week-old
mice at 1 × 1012 GC per mouse. Mice were given a HFD at 10–11 weeks of age.
HFD was 45% fat D12451, Research Diets.
Islet isolation and glucose-stimulated insulin secretion assay (GSIS). Primary
islets were isolated from the pancreas of 8–13-week-old C57BL/6N male mice via
collagenase P (Roche) digestion as described above, followed by a centrifugation
step using Optiprep density gradient (Sigma). Isolated islets were handpicked twice
and incubated in RPMI supplemented with 10 % v/v FBS and 1 % v/v P/S O/N for
recovery. The next day, islets were treated with various concentrations of the
commercially available bacterial FNDC4 (Adipogen), the in-house produced
mammalian FcsFNDC4, or the corresponding negative controls PBS and Fc-
peptide for 24 h. To gain sufficient islet numbers, islets of two mice were pooled for
each biological replicate. For the GSIS assay, 9 islets of comparable size were
transferred per well into a low-attachment V-shaped 96-well plate. Islets were
incubated in modified Krebs Ringer phosphate HEPES buffer (KRPH; 115 mM
NaCl, 4.7 mM KCl, 1.2 mM KH2PO4, 1.2 mM MgSO4·7H2O, 20 mM NaHCO3
20mM, 16 mM HEPES, 2.56 mM CaCl2·2H2O) supplemented with 0.1 % BSA
(RIA grade) with various glucose concentrations in the presence of the proteins
described above. Exendin-4 served as positive control. After incubation in the
presence of 1 mM glucose for 1 h, islets were sequentially incubated with 2.8 mM
glucose (low glucose) and 16.7 mM glucose (high glucose) for 30 min each. In
between the incubation steps, islets were washed twice using KRPH with 2.8 mM
glucose. Insulin concentration in the supernatant was assessed using the mouse
insulin ELISA kit from ALPCO.
C-peptide and insulin measurements. For measurements of C-peptide in plasma,
C-peptide quantification kit from CrystalChem was used (cat.# 90050) and for
measuring C-peptide in serum the C-peptide quantification kit from ALPCO (cat.
no.: 80-CPTMS-E01) was used, according to the manufacturer’s description.
Insulin was measured with a commercial kit from ALPCO (cat. no.: 80-INSHU-
E01.1).
Cytokine and adipokine ELISA. ELISA quantification of TNFalpha, leptin, adi-
ponectin, and resistin was performed according to the kit’s instructions—R&D
Systems.
Therapeutic injections of FcsFNDC4 to HFD (60% fat) mice. WT C57BL6N,
male mice were fed on a HFD with 60% fat (Research Diets Cat. # D12492) for
16 weeks, starting from 8 to 9 weeks of age. Mice were given ip injections of
FcsFNDC4 (0.2 mg/kg) or vehicle control (PBS) every second day for 4 weeks,
while mice still on HFD (60% fat). Glucose clearance and insulin tolerance was
assessed with an IPGTT and ip ITT.
2-NBDG tissue uptake quantification: Male C57BL6N mice were on HFD (45%
fat) for 20 weeks and in the last weeks (16–20 weeks) were injected ip every other
days with FcsFNDC4 (0.2 mg/kg) or vehicle control. Prior the IPGTT with
fluorescent glucose (2-NBDG), mice were fasted for 6 h and were injected ip with a
mix of normal D-glucose (2g/kg, 40%v/v) with 2% 2-NBDG glucose (stock
concentration 5 mg/ml—ThermoFisher, cat.# N13195). Mice were sacrificed at 35
min after injection, which based on pilot studies was the time point 5 min after all
mice had shown a peak in blood glucose (peak was at 30 min). Tissues were
collected and snap frozen in liquid N. Tissues were weighed and homogenized in
RIPA buffer and fluorescence was measured in a plate reader.
Glucose and ITT. Before testing mice were placed in a new cage and food was
removed for 6 h. After this period of fasting, we assessed glucose tolerance by ip
injection of 2 g/kg D-glucose at time point 0 min and subsequent measurements of
blood glucose at 0, 15, 30, 60, 90, 120, and 180 min using ACCU-CHEK glucometer
strips. To measure glucose-induced insulin secretion, we collected blood at 0, 15,
30, and 90 min in EDTA-coated tubes. Plasma was collected after spinning the
blood at 2000 × g for 10 min. To assess insulin tolerance, we measured blood
glucose levels at several times points after ip injection of insulin. Insulin used was
Humulin.
Histology. Liver and AT tissue samples were fixed in neutrally buffered 4% for-
maldehyde solution for 24 h (Formalin 10% neutral buffered, HT501128, Sigma-
Aldrich, Germany) and subsequently routinely embedded in paraffin (Tissue Tec
VIP.5, Sakura Europe, Netherlands). Sections of 3 µm nominal thickness were
stained with hematoxylin and eosin (H&E), using a HistoCore SPECTRA ST
automated slide stainer (Leica, Germany) with prefabricated staining reagents
(Histocore Spectra H&E Stain System S1, Leica, Germany), according to the
manufacturer’s instructions. Histopathological examination was performed by a
pathologist in a blinded fashion (i.e., without knowledge of the treatment–group
affiliations of the examined slides). Immunohistochemical (IHC) detection of
CD68 in eWAT and iWAT sections was performed on a Ventana Discovery Ultra-
stainer (Roche Diagnostics, Germany), using specific antibodies (polyclonal rabbit
anti-CD68 antibody, #125212, Abcam, USA, and secondary antibody: goat anti-
rabbit IgG antibody (H+ L), biotinylated, BA-1000, Vector, Germany) and pre-
fabricated solutions (DISCOVERY DAB Map Detection Kit, Cat. 760-124, Roche,
USA). All IHC analyses included appropriate negative control slides (omission of
the first antibody). H&E-stained slides and IHC sections were digitally scanned
with an Axio Scan.Z1 scanner (Zeiss, Germany), using a ×20 objective. Automated
digital image analysis (Definiens Developer XD 2, Definiens AG, Germany) was
used for determination of the mean adipocyte section profile areas, as well as the
numbers of CD68-positive macrophage cell section profiles and the percentage of
CD68-positive stained area per total AT section area.
Tissue lipid extraction and TG measurements. Lipid were extracted according to
Folch method47. Briefly 10–100 mg of frozen wet tissue were weighed, to which 1.5
ml of chloroform:methanol (2:1) mixture (maintained at −80 °C; final volume is
about 1.6 ml) were added. Tissues were lysed with the Qiagen TissueLyser (2 × 30 s,
30 Hz) until no visible large particles remained. The lysed solution was spun down
briefly and mixed for 20 min on Thermomixer at 1400 rpm, RT and centrifuged for
30 min at 13,000 rpm at 20 °C. Afterwards, 1 ml of supernatant (i.e., liquid phase)
was transferred to a new 2-ml tube and 200 μl of 150 mM (0.9%) NaCl was added
and mixed by vigorous shaking and centrifuged for 5 min at 2000 rpm. The
resulted lower organic phase was transferred into new tube containing the
chloroform:Triton-X (40 µl of chloroform:Triton-X (1:1) solution). This solution
was dried with the speedvac O/N (or until no change in tube weight) and the
remaining triton–lipid solution was resuspended in 200 µl of dH2O and nixed by
1 h rotation at RT and then stored at −80 °C until use (final volume 225 µl, 1.125
dilution factor). TGs were measured by the Sigma Triglyceride determination Kit,
Cat. # TR0100.
Tritium 2-deoxyglucose uptake assay. 3T3-L1 adipocytes in 12-well plates were
washed twice and incubated with serum- and bicarbonate-free DMEM containing
20 mM HEPES, pH 7.4, and 0.2% BSA for 2 h. Following 3-h serum starvation, cells
were washed twice with Krebs–Ringer phosphate buffer (0.6 mM Na2HPO4, 0.4
mM NaH2PO4, 120 mM NaCl, 6 mM KCl, 1 mM CaCl2, 1.2 mM MgSO4, 12.5 mM
HEPES, pH 7.4) supplemented with 0.2% BSA. Indicated dose of insulin was added
for 20 min, and glucose transport was initiated by the addition of [3H]-2DG
(PerkinElmer Life Sciences) (0.25 μCi/well, 50 μM unlabeled 2-deoxyglucose) for
5 min. To determine non-specific glucose uptake, 25 μM cytochalasin B was added
prior to the addition of [3H]-2DG. Uptake was terminated with three rapid washes
in ice-cold PBS, after which the cells were solubilized in 1% Triton X-100 in PBS.
Samples were assessed for radioactivity by scintillation counting. Each condition
was performed in triplicate.
For calculation of uptake, non-specific uptake was subtracted by the specific
uptake and values were normalized for protein concentration.
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FNDC4 signaling in 3T3L1 adipocytes and primary mouse SVF-derived
adipocytes
3T3L1 differentiation protocol. Differentiation of 3T3L1 to mature adipocytes was
done according to the protocol by Zebish et al.46. Experiments were performed of
days 8–12 of differentiation and passage numbers between 15 and 20.
Induction of in vitro insulin resistance and long-term incubation with FcsFNDC4.
Insulin resistance was induced on 3T3L1 mature adipocytes by O/N (16 h) expo-
sure to 10 nM insulin, in DMEM high glucose, 10% FBS, 1% P/S (complete media),
according to the protocol of Tan et al.14. Different concentrations of FcsFNDC4 or
Fc controls were added to the cells for 16 h together with insulin (10 nM), with or
without anti-GPR116 (ab111169) or isotype control. Also cells without insulin were
included (w/o), as control for the 16 h insulin effect. After 16-h incubation
described above, media was removed and cells were washed twice with PBS. Cells
were incubated in serum-free high glucose DMEM for 3 h and then fresh serum-
free high glucose DMEM containing different concentrations of insulin (0nM,
0.5nM, 1 nM) were added to the cells for 5 min. At that time, media was removed
and cells were washed twice with ice-cold PBS and lysed in 1x cell lysis buffer from
Cell Signaling, Cat. # 9803 with additional protease and phosphatase inhibitors.
For the short-term co-stimulation with FcsFNDC4 and insulin: 3T3L1 mature
adipocytes were incubated for 3 h in serum-free, high glucose DMEM. 30 min
before the co-stimulation with insulin and FcsFNDC4, anti-GPR116 (ab111169) or
isotype control was added to the media. Then media was changed to fresh serum-
free, high glucose DMEM with insulin and FcsFNDC4 for 5 min.
Differentiation of mouse primary SVF to mature adipocytes. Primary SVF cells were
isolated by 8 min collagenase II (Life Technologies, Cat # 17101015) digestion of
inguinal WAT (after removal of the lymph node) from male mice, 6–8 weeks old.
SVF preadipocytes were grown till confluence in DMEM high glucose, 10% FBS+ 1%
P/S, when differentiation was initiated with the addition of dexamethasone (2 ng/ml),
IBMX (122 ng/ml), T3 (6.7 ng/ml), insulin (0.865 ng/ml) and Rosiglitazone (5 ng/ml)
for 2 days. On day 3, media was changed to complete media containing 0.865 ng/ml
insulin for 2 days, and on day 5, the media was changed in complete media containing
0.4325 ng/ml insulin, in which they were maintained. Experiments were performed
between day 6 and day 8 post differentiation, in serum-free, DMEM high glucose
media, after 3 hr starvation in serum-free, DMEM high glucose media.
Incubation of 3T3L1 with palmitate. Sodium palmitate (Sigma) was conjugated
with 2% BSA (fatty acid free), dissolved in DMEM, and applied to the adipocytes to
a final concentration of 200 μM for 24 h with or without FcsFNDC4 (200 nM) or Fc
(200 nM) control.
Western blot. Soluble lysates were collected by centrifugation at 15,000 × g for 15
min. Samples were boiled for 7 min in Laemmli buffer and loaded to a Tris-glycine
gel. For receptor blots, samples were warmed at 70 °C for 30 min and not boiled.
Proteins were transferred to a PVDF membrane with semi-dry transfer for 14 min
at constant 1.4 mA using the Trans-Blot Turbo transfer system from BIO-RAD.
Membranes were blocked with 5% milk for 30 min and incubated O/N with the
primary antibody (1:1000) in 2% milk. Washes were done with 0.1% and 0.05%
TBS-Tween buffer and secondary antibody was used 1:1000 for 1 h at RT. Anti-
bodies used in this study are listed below (Table 1). Membranes were stripped and
reblotted. In all blots presented in the manuscript, loading control has been run on
the same blot as the protein assessed.
Metabolic phenotyping (TSE phenotyping). EE, locomotor activity, RER, and
food intake were measured by combined indirect calorimetry over 93.4 h (Phe-
noMaster; TSE Systems, Bad Homburg vor der Höhe, Germany) as described
previously48.
Chronically injected mice with FcsFNDC4 were WT C57BL6N, male mice fed
on a HFD with 45% fat (Cat. # D12451) for 16 weeks, starting from 8 to 9 weeks of
age. Mice were given i.p. injections of FcsFNDC4 (0.2 mg/kg) or Fc negative
control (0.2 mg/kg) every second day for 4 weeks while mice still on HFD
(60% fat).
Single-dose injection of FcsFNDC4: Young male mice, 12–14 weeks old were
put in the PhenoMaster for 4 days to acclimatize. On the day of the experiment,
food was removed 4 h before the injection of rec. protein, when FcsFNDC4 or Fc
control, 1 mg/kg, were injected i.p. to the mice. Measurement of EE, RER, and
locomotor activity were collected for 2 h post injection, when the experiment was
terminated.
Altered feeding experiments in mice. All mice were maintained on a daily cycle
of 12-h light (06:00–18:00) and 12-h darkness (18:00–06:00). For CR: ad libitum
groups were allowed free access to either standard chow (AL chow) or HFD 45%
fat (D12451, Research Diets) for 17 weeks, while the food intake of CR groups (CR
chow and CR HFD) was reduced by ~11% for 17 weeks, when the animals were
sacrificed and organs harvested. For intermittent fasting: mice from 6 weeks of age
were put under cycles of 24 h fasting followed by 48 h refeeding. During the fasting,
only access to water was available and during the refeeding mice had ad libitum
access to food. All groups were maintained on this feeding cycle either on chow or
HFD 45% fat (D12451, Research Diets) for 17 weeks. Blood was collected from the
trunk after decapitation.
Table 1 Antibody ID and working dilutions.
Antibodies Supplier Cat. no. Working dilution, application
Anti-P-ERK1/2 Cell Signaling Technology Cat.# 9101 1:1000 WB
Anti-ERK1/2 Cell Signaling Technology Cat. # 4695 1:1000 WB
Anti-GPR116 Abcam Cat.# ab136262 1:1000 WB
Anti-GPR116 Abcam Cat.# ab111169 1:1000 WB 0.4 μg/ml as a blocking antibody
in vitro
Anti-FNDC4 Sigma Aldrich Cat. # SAB1401807 1:1000 WB
Anti-beta tubulin Sigma Aldrich Cat. # T5201 1:1000 WB
Anti-VCP Abcam Cat. # ab109240 1:1000 WB
Monoclonal ANTI-FLAG® M2-Peroxidase (HRP) Sigma Aldrich Cat. # A8592 1:1000 WB
Anti-rabbit, HRP conjugated DAKO Cat.# P0399 1:10,000 WB
Anti-mouse IgG-HRP conjugated DAKO Cat.# P0447 1:10,000 WB
Anti-F(ab’)2-goat anti-human IgG Fc secondary
antibody, PE
Invitrogen Cat.# H10104 1:200 FACS
Anti- Cd68 Abcam Cat.# ab125212 1:500 IHC
Anti-beta actin Sigma Aldrich Cat.# A5441 1:1000 WB
Anti-pAS160(Thr642) Cell Signaling Technology Cat.# 4288 1:1000 WB
Anti-AS160 Cell Signaling Technology Cat.# 2670S 1:1000 WB
Anti-pAKT(Ser473) Cell Signaling Technology Cat.# 9271S 1:1000 WB
Anti-AKT Cell Signaling Technology Cat.# 9272 1:1000 WB
Anti-phopho-PKA substrate Cell Signaling Technology Cat.# 9624 1:1000 WB
Anti-pCREB(Ser133) Cell Signaling Technology Cat.# 9198 1:1000 WB
Anti-pAMPKa(Thr172) Cell Signaling Technology Cat.# 2535 1:1000 WB
Anti-HO-1 Cell Signaling Technology Cat.# 43966 1:1000 WB
Anti-pSTAT3(Tyr705) Cell Signaling Technology Cat.# 9145 1:1000 WB
Anti-STAT3 Cell Signaling Technology Cat.# 12640 1:1000 WB
Anti-phopsho-PKC substrate Cell Signaling Technology Cat.# 6967 1:1000 WB
Secondary antibody: goat anti rabbit-biotinylated Vector BA-1000 1:750 IHC
Rabbit IgG, polyclonal—isotype control (ChIP grade) Abcam Cat.# 171870 0.4 μg/ml as a blocking antibody in vitro
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Real-time quantitative PCR. mRNA was extracted with the TRIzol reagent
(Invitrogen, ThermoFisher Scientific). For mouse and cell experiments, mRNA
500 ng–1 μg of RNA was amplified with the RevertAid First Strand cDNA
Synthesis Kit Cat. # K1622. cDNA was PCR amplified with TaqMan Gene
Expression Master Mix Cat. # 4369016 and PowerUp SYBR Green Master Mix 5x,
Cat. # A25777. qPCR primers were designed to span exon–exon sequences to
generate a product of 100–200 bp and sequences were derived either from the
validated Primerbank (http://pga.mgh.harvard.edu/primerbank) or from the pub-
lished literature. The sequence of primers and Taqman probe identity is given in
Supplementary Table 3. The mRNA levels of each gene was calculated with the
2^ddCt method and normalized for the expression mRNA of the housekeeping
gene (as indicated in the figure legends). We used Applied Biosystems QuantStudio
6 and 7 Flex Real-Time PCR, ThermoFisher.
Quantification and statistical analysis. All values in graphs are presented as
mean ± SEM. Two-way analysis of variance for multiple comparison were used to
analyze the data. Significant differences between two groups were evaluated
using a two-tailed, unpaired or paired Student’s t test as the sample groups dis-
played a normal distribution and comparable variance (*p < 0.05, **p < 0.01,
***p < 0.001). In most figures exact p-values are shown.
For quantification of western blots, we performed band densitometric analysis
(in Supplementary Fig. S7 are the quantification of band intensities is shown),
using Image Lab version 5.2.1 build 11 (BIO-RAD).
Reproducibility. We repeated key experiments several times and the time of
repetitions for each experiment with same results is mentioned in the figure
legends.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Source data are provided with this paper. Mouse models are available with MTA
agreement. All data supporting the findings within the article and its supplementary
information files are available from the corresponding authors upon request. Microarray
data are available in GEO under the number: GSE165329. pTPM data for FNDC4
expression are available from Protein Atlas and exact URLs for each tissue are included
in the Source data file.
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